Robotic versus open radical cystectomy for bladder cancer in adults by Rai, Bhavan Prasad et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1002/14651858.CD011903.pub2
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Rai, B. P., Bondad, J., Vasdev, N., Adshead, J., Lane, T., Ahmed, K., ... Aboumarzouk, O. M. (2019). Robotic
versus open radical cystectomy for bladder cancer in adults. The Cochrane database of systematic reviews, 4,
CD011903. https://doi.org/10.1002/14651858.CD011903.pub2
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 23. May. 2019
Cochrane Database of Systematic Reviews
Robotic versus open radical cystectomy for bladder cancer in
adults (Review)
Rai BP, Bondad J, Vasdev N, Adshead J, Lane T, Ahmed K, Khan MS, Dasgupta P, Guru K, Chlosta
PL, Aboumarzouk OM
Rai BP, Bondad J, Vasdev N, Adshead J, Lane T, Ahmed K, KhanMS, Dasgupta P, Guru K, Chlosta PL, Aboumarzouk OM.
Robotic versus open radical cystectomy for bladder cancer in adults.
Cochrane Database of Systematic Reviews 2019, Issue 4. Art. No.: CD011903.
DOI: 10.1002/14651858.CD011903.pub2.
www.cochranelibrary.com
Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
17DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
23CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
43DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 1 Recurrence-free
survival. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
Analysis 1.2. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 2 Major postoperative
complication rates (Clavien 3 to 5). . . . . . . . . . . . . . . . . . . . . . . . . . . 44
Analysis 1.3. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 3 Minor postoperative
complication rates (Clavien 1 and 2). . . . . . . . . . . . . . . . . . . . . . . . . . . 45
Analysis 1.4. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 4 Transfusion rate. 46
Analysis 1.5. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 5 Hospital stay. . 47
Analysis 1.6. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 6 Quality of life. 48
Analysis 1.7. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 7 Positive margin. 49
49APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
50CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
51SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
52DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
52NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iRobotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Robotic versus open radical cystectomy for bladder cancer in
adults
Bhavan Prasad Rai1, Jasper Bondad2 , Nikhil Vasdev3, Jim Adshead3, Tim Lane3, Kamran Ahmed4, Mohammed S Khan4, Prokar
Dasgupta4 , Khurshid Guru5, Piotr L Chlosta6, Omar M Aboumarzouk7
1Department of Urology, Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne,
UK. 2Department of Urology, Southend Hospital, Westcliff-on-Sea, UK. 3Department of Urology, Lister Hospital, Stevenage, UK.
4MRC Centre for Transplantation, Division of Transplantation Immunology and Mucosal Biology, School of Medicine, King’s College
London, London, UK. 5Department of Urology, Roswell Park Cancer Institute, Buffalo, New York, USA. 6Department of Urology,
Jagiellonian University, Collegium Medicum, Krakow, Poland. 7Department of Urology, NHS Greater Glasgow and Clyde, Glasgow,
UK
Contact address: Omar M Aboumarzouk, Department of Urology, NHS Greater Glasgow and Clyde, Queen Elizabeth University
Hospital, Glasgow, Scotland, UK. aboumarzouk@gmail.com, drbigo31262@gmail.com.
Editorial group: Cochrane Urology Group.
Publication status and date: New, published in Issue 4, 2019.
Citation: Rai BP, Bondad J, Vasdev N, Adshead J, Lane T, Ahmed K, Khan MS, Dasgupta P, Guru K, Chlosta PL, Aboumarzouk
OM. Robotic versus open radical cystectomy for bladder cancer in adults. Cochrane Database of Systematic Reviews 2019, Issue 4. Art.
No.: CD011903. DOI: 10.1002/14651858.CD011903.pub2.
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
It has been suggested that in comparison with open radical cystectomy, robotic-assisted radical cystectomy results in less blood loss,
shorter convalescence, and fewer complications with equivalent short-term oncological and functional outcomes; however, uncertainty
remains as to the magnitude of these benefits.
Objectives
To assess the effects of robotic-assisted radical cystectomy versus open radical cystectomy in adults with bladder cancer.
Search methods
Review authors conducted a comprehensive search with no restrictions on language of publication or publication status for studies
comparing open radical cystectomy and robotic-assisted radical cystectomy. The date of the last search was 1 July 2018 for the Cochrane
Central Register of Controlled Trials, MEDLINE (1999 to July 2018), PubMed Embase (1999 to July 2018), Web of Science (1999 to
July 2018), Cancer Research UK (www.cancerresearchuk.org/), and the Institute of Cancer Research (www.icr.ac.uk/). We searched the
following trials registers: ClinicalTrials.gov (clinicaltrials.gov/), BioMed Central International Standard Randomized Controlled Trials
Number (ISRCTN) Registry (www.isrctn.com), and the World Health Organization International Clinical Trials Registry Platform.
Selection criteria
We searched for randomised controlled trials that compared robotic-assisted radical cystectomy (RARC) with open radical cystectomy
(ORC).
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Data collection and analysis
This study was based on a published protocol. Primary outcomes of the review were recurrence-free survival and major postoperative
complications (class III to V). Secondary outcomes were minor postoperative complications (class I and II), transfusion requirement,
length of hospital stay (days), quality of life, and positive margins (%). Three review authors independently assessed relevant titles and
abstracts of records identified by the literature search to determine which studies should be assessed further. Two review authors assessed
risk of bias using the Cochrane risk of bias tool and rated the quality of evidence according to GRADE. We used Review Manager 5
to analyse the data.
Main results
We included in the review five randomised controlled trials comprising a total of 541 participants. Total numbers of participants
included in the ORC and RARC cohorts were 270 and 271, respectively.
Primary outomes
Time-to-recurrence: Robotic cystectomy and open cystectomy may result in a similar time to recurrence (hazard ratio (HR) 1.05, 95%
confidence interval (CI) 0.77 to 1.43); 2 trials; low-certainty evidence). In absolute terms at 5 years of follow-up, this corresponds to
16 more recurrences per 1000 participants (95% CI 79 fewer to 123 more) with 431 recurrences per 1000 participants for ORC. We
downgraded the certainty of evidence for study limitations and imprecision.
Major complications (Clavien grades 3 to 5): Robotic cystectomy and open cystectomy may result in similar rates of major compli-
cations (risk ratio (RR) 1.06, 95% CI 0.76 to 1.48); 5 trials; low-certainty evidence). This corresponds to 11 more major complications
per 1000 participants (95% CI 44 fewer to 89 more). We downgraded the certainty of evidence for study limitations and imprecision.
Secondary outcomes
Minor complications (Clavien grades 1 and 2):We are very uncertain whether robotic cystectomy may reduce minor complications
(very low-certainty evidence). We downgraded the certainty of evidence for study limitations and for very serious imprecision.
Transfusion rate:Robotic cystectomy probably results in substantially fewer transfusions than open cystectomy (RR 0.58, 95%CI 0.43
to 0.80; 2 trials; moderate-certainty evidence). This corresponds to 193 fewer transfusions per 1000 participants (95% CI 262 fewer
to 92 fewer) based on 460 transfusion per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations.
Hospital stay: Robotic cystectomy may result in a slightly shorter hospital stay than open cystectomy (mean difference (MD) -0.67,
95%CI -1.22 to -0.12); 5 trials; low-certainty evidence).We downgraded the certainty of evidence for study limitations and imprecision.
Quality of life: Robotic cystectomy and open cystectomy may result in a similar quality of life (standard mean difference (SMD) 0.08,
95% CI 0.32 lower to 0.16 higher; 3 trials; low-certainty evidence). We downgraded the certainty of evidence for study limitations
and imprecision.
Positive margin rates: Robotic cystectomy and open cystectomy may result in similar positive margin rates (RR 1.16, 95% CI 0.56 to
2.40; 5 trials; low-certainty evidence). This corresponds to 8 more (95%CI 21 fewer to 67 more) positive margins per 1000 participants
based on 48 positive margins per 1000 participants for ORC. We downgraded the certainty of evidence for study limitations and
imprecision.
Authors’ conclusions
Robotic cystectomy and open cystectomy may have similar outcomes with regard to time to recurrence, rates of major complications,
quality of life, and positive margin rates (all low-certainty evidence). We are very uncertain whether the robotic approach reduces
rates of minor complications (very low-certainty evidence), although it probably reduces the risk of blood transfusions substantially
(moderate-certainty evidence) and may reduce hospital stay slightly (low-certainty evidence). We were unable to conduct any of the
preplanned subgroup analyses to assess the impact of patient age, pathological stage, body habitus, or surgeon expertise on outcomes.
This review did not address issues of cost-effectiveness.
P L A I N L A N G U A G E S U M M A R Y
Robotic versus open radical cystectomy for bladder cancer in adults
Review question
2Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
For patients with bladder cancer that involves the deep muscle wall, does use of a robotic device lead to better or worse outcomes than
open surgery?
Background
Patients with bladder cancer that involves the deep muscle wall are best treated by an operation that removes the entire bladder and
creates an artificial bladder or channel from the bowel to allow urine to drain to the outside world. This has been done traditionally
through open surgery using one large incision. Recently, this operation has been performed with robotic assistance using several small
incisions. It is uncertain which approach is better.
Study characteristics
We performed a comprehensive literature search until 1 July 2018. We found five trials comparing robotic assisted versus open surgery.
The total number of participants in these trials was 541. Four studies were conducted in the USA and one in the UK.
Key results
There may be little to no difference in the time to recurrence, the rate of major complications or minor complications, quality of
life, and rates of positive margins (signalling that cancer may have been left behind). Robotic surgery probably results in fewer blood
transfusions and may lead to a slightly shorter hospital stay when compared with open surgery.
Certainty of evidence
Reviewers rated the certainty of evidence as low for most outcomes, except for minor complications (very low) and transfusions
(moderate). This means that the true results for these outcomes could be quite different.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Robotic-assisted laparoscopic vs open radical cystectomy for bladder cancer in adults
Patient or population: bladder cancer in adults
Setting: tert iary care centres in the United States and the United Kingdom
Intervention: robot ic-assisted laparoscopic cystectomy
Comparison: open radical cystectomy
Outcomes No. of participants
(studies)
Follow-up
Certainty of the evidence
(GRADE)
Relative effect
(95% CI)
Anticipated absolute effects* (95% CI)
Risk with open radical cys-
tectomy
Risk difference with robotic-
assisted laparoscopic cys-
tectomy
Time to recurrence (here:
recurrence rate at 5 years)1
assessed with clinical ex-
aminat ion and imaging
277
(2 RCTs)
⊕⊕©©
LOWa,b
HR 1.05
(0.77 to 1.43)
Study populat ion
431 per 1000 16 more per 1000
(79 fewer to 123 more)
Major postoperat ive com-
plicat ions
assessed with Clavien-
Dindo system (rated grade
3 to 5)
541
(5 RCTs)
⊕⊕©©
LOWb,c
RR 1.06
(0.76 to 1.48)
Study populat ion
185 per 1000 11 more per 1000
(44 fewer to 89 more)
Minor post-
operat ive complicat ions as-
sessed with Clavien-Dindo
system (rated grade 1 or 2)
423
(4 RCTs)
⊕©©©
VERY LOWc,d
RR 0.82
(0.58 to 1.17)
Study populat ion
443 per 1000 80 fewer per 1000
(186 fewer to 75 more)
Transfusion rate assessed
with transfused units of
packed red blood cells
326
(2 RCTs)
⊕⊕⊕©
MODERATEc
RR 0.58
(0.43 to 0.80)
Study populat ion
460 per 1000 193 fewer per 1000
(262 fewer to 92 fewer)
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Hospital stay assessed in
days
541
(5 RCTs)
⊕⊕©©
LOWb,c
- Mean hospital stay ranged
f rom 5.1 to 11.9 days
MD 0.67 days lower
(1.22 lower to 0.12 lower)
Quality of lif e (higher scores
indicate better quality of
lif e)
assessed with SMD calcu-
lated f rom various validated
quality of lif e instruments
Scale f rom 0 to 1
270
(3 RCTs)
⊕⊕©©
LOWc,e
- Mean quality of lif e (higher
scores indicate better quality
of lif e) was 0 SD
SMD 0.08 SD lower
(0.32 lower to 0.16 higher)
Posit ive margins assessed
through pathological evalu-
at ion of cystectomy speci-
men
541
(5 RCTs)
⊕⊕©©
LOWb,c
RR 1.16
(0.56 to 2.40)
Study populat ion
48 per 1000 8 more per 1000
(21 fewer to 67 more)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; HR: hazard rat io; MD: mean dif ference; RCT: randomised controlled trial; RR: risk rat io; SMD: standardised mean dif ference
GRADE Working Group grades of evidence.
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: We are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: Our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: We have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The control event rate at 5 years was based on an overall recurrence rate of 25/ 58 (43.1%) in the ORC arm reported in
Bochner 2015
aDowngraded by one level for study lim itat ions; risk of performance, detect ion, and attrit ion bias.
bDowngraded by one level for imprecision: wide conf idence intervals consistent with both no ef fect and clinically important
benef it or harm.
cDowngraded by one level for study lim itat ions; risk of performance and detect ion bias.
dDowngraded by two levels for very serious imprecision: wide conf idence interval consistent with small benef it , no ef fect, and
small harm.
eDowngraded by one level for imprecision: wide conf idence intervals consistent with both no ef fect and clinically important
reduct ion in quality of lif e, assuming SMD of 0.2.
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B A C K G R O U N D
Description of the condition
Over 400,000 new cases of bladder cancer are diagnosed annu-
ally, accounting for 3% of all cancers (Ferlay 2013; Ferlay 2015;
Ploeg 2009). Radical cystectomy (RC) with pelvic lymph node
dissection (PLND) and urinary diversion is the gold standard sur-
gical treatment for muscle-invasive bladder cancer (MIBC) (Hayn
2010; Jonsson 2011; Lee 2011; Redorta 2010; Smith 2011;Witjes
2014). Other indications for RC include high-risk non-muscle-
invasive bladder cancer (NMIBC) and recurrent multifocal su-
perficial disease (Hayn 2010; Jonsson 2011; Lee 2011; Redorta
2010; Smith 2011; Witjes 2014). The procedure has traditionally
been performed using an open approach. Morbidity with open
radical cystectomy (ORC) is high. In a retrospective review of a
prospectively maintained database of 1142 patients who under-
went ORC/urinary diversion by high-volume fellowship-trained
urological oncologists, the reported 90-day overall complication
rate and the 30-day mortality rate were 64% and 1.5%, respec-
tively (Shabsigh 2009).
Description of the intervention
A significant interest in minimally invasive surgery (MIS) has
arisen in the last two decades in an attempt to reduce morbidity,
expedite recovery, and decrease hospital stay (Hu 2009; Schwenk
2005; Wright 2013). MIS approaches, both conventional la-
paroscopy and robotic-assisted approaches, have replaced a sig-
nificant number of open surgical techniques (Hu 2009; Schwenk
2005;Wright 2013). The uptake of conventional laparoscopic rad-
ical cystectomy has been impeded by technical challenges associ-
ated with the procedure, in particular the reconstructive aspects of
the procedure (Aboumarzouk 2012; Aboumarzouk 2013; Castillo
2006; Castillo 2009; Cathelineau 2005; Haber 2008; Hosseini
2011; Huang 2008; Huang 2010; Jonsson 2011; Khan 2011;
Sighinolfi 2007; Smith 2011). Robotic-assisted radical cystectomy
(RARC)-which offers such advantages as increased manoeuvra-
bility, superior magnification, enhanced EndoWrist® dexterity,
and tremor elimination-has been suggested as an alternative to
overcome issues associated with the conventional laparoscopic ap-
proach (Ishii 2014).
How the intervention might work
Adoption of the robotic approach has been swift in contempo-
rary urological practice, with widespread application of robotic-as-
sisted radical prostatectomy and robotic-assisted partial nephrec-
tomy in Europe and the USA leading to favourable perioperative
outcomes in comparison with open and laparoscopic counterparts
(Novara 2012). Three systematic reviews of randomised and non-
randomised controlled trials suggested shorter operative time and
less blood loss for ORC when compared with RARC (Ishii 2014;
Novara 2015; Tang 2014). These reviews also demonstrated re-
duced Clavien grade 3 complications for RARC. Two comparative
studies have suggested similar survival outcomes between ORC
and RARC (Khan 2012; Nepple 2013).
Why it is important to do this review
Although over 2000 procedures have been reported to the Inter-
national Robotic Cystectomy Consortium from 37 centres world-
wide, well-conducted studies comparingRARCs toORCs are lack-
ing (Raza 2015). Randomised controlled trials are necessary to es-
tablish how RARC compares to ORC.We performed a systematic
review to summarise and critically appraise the body of evidence
comparing these two approaches to inform clinical decision-mak-
ing as well as health policy.
O B J E C T I V E S
To assess the effects of robotic-assisted radical cystectomy versus
open radical cystectomy in adults with bladder cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) and quasi-
RCTs of individual participants comparing ORC and RARC. We
didnot include cluster-randomised trials.We considered all studies
regardless of their publication status and language of publication.
Types of participants
We included adult participants with a diagnosis of bladder ma-
lignancy who were undergoing radical cystectomy as part of their
treatment for pathologically provenMIBC or high-grade NMIBC
(T1-4/carcinoma in situ (CIS), N0M0). We included participants
irrespective of histological bladder cancer type (i.e. we included
those with urothelial cell carcinoma, squamous cell carcinoma, or
adenocarcinoma).We included participants receiving neoadjuvant
or adjuvant chemotherapy. We excluded studies of participants
with prior radiotherapy in which cystectomy was performed as a
salvage procedure.
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Types of interventions
We investigated the following comparison of experimental inter-
vention versus comparator intervention. We included trials inde-
pendent of the urinary diversion method employed. We analysed
data by intention-to-treat analysis.
Experimental intervention
Robotic-assisted radical cystectomy.
Comparator intervention
Open radical cystectomy.
Types of outcome measures
Primary outcomes
• Time to recurrence
• Major postoperative complications (class III to V) (Dindo
2004)
Secondary outcomes
• Minor postoperative complications (class I and II) (Dindo
2004)
• Transfusion requirement
• Length of hospital stay (days)
• Quality of life as evaluated via validated participant-
reported questionnaire scores or domains reflecting overall or
global health of the participant
• Positive margins (%)
Search methods for identification of studies
Electronic searches
We performed a comprehensive search with no restrictions on
language of publication nor publication status. We searched the
following electronic databases (date of last search was 1 July 2018):
• Cochrane Central Register of Controlled Trials
(CENTRAL; latest issue) in the Cochrane library via Wiley
• MEDLINE (1999 to July 2018); PubMed search. We used
these terms and medical subject heading (MeSH) phrases:
(cystectomy [MeSH terms] AND robotic AND open) AND
“surgery” [MeSH subheading]
• EMBASE (1999 to July 2018); Ovid search using the terms
cystectomy, open, and robotic
• Web of Science (1999 to July 2018)
• Cancer Research UK (www.cancerresearchuk.org/)
• Institute of Cancer Research (www.icr.ac.uk/)
We searched the following trials registers:
• ClinicalTrials.gov (clinicaltrials.gov/)
• BioMed Central ISRCTN registry (www.isrctn.com)
• World Health Organization International Clinical Trials
Registry Platform (WHO ICTRP; www.who.int/ictrp/en/)
See Appendix 1 for search terms used in strategies for this review.
We limited back-searching from 1999 onward because the earliest
da Vinci robotic-assisted device was not introduced until 1999
(Ballantyne 2003).
Searching other resources
We further evaluated the reference lists of included studies and
of relevant review articles identified by the search. To identify
unpublished studies, we searched the online conference proceed-
ings of annual meetings of the American Urological Association
(www.auanet.org) and the European Association of Urology (http:
//uroweb.org) from 2012 to July 2018.
Data collection and analysis
Selection of studies
Three review authors (BR, OMA, JB) independently assessed rele-
vant titles and abstracts of records identified by the literature search
to determine which studies should be assessed further. Three re-
view authors (BR, OMA, JB) investigated all potentially relevant
records as full text, mapped records to unique studies, and classi-
fied studies as included studies, excluded studies, studies awaiting
classification, or ongoing studies, in accordance with the criteria
for each provided in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). We resolved any disagreement by
discussion and consensus or by recourse to a fourth review author
(KG). We adapted a PRISMA flow diagram to demonstrate the
process of study selection (Liberati 2009).
Data extraction and management
For studies that fulfil inclusion criteria, three review authors (BR,
OMA, JB) independently extracted the following information,
which is provided in the Characteristics of included studies tables:
• Study design (e.g. parallel-group randomised trial)
• Study dates (if dates were not available, this was reported)
• Study settings and country
• Participant inclusion and exclusion criteria
• Participant details and baseline demographics, such as age
and sex
• Numbers of participants by study and by study arm
• Details of relevant experimental and comparator
interventions and conversion rates from robotic to open
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• Definitions of relevant outcomes and methods and timing
of outcome measurement, as well as any relevant subgroups
• Study funding sources
• Declarations of interest by primary investigators
For dichotomous outcomes, we attempted to obtain numbers of
events and totals for populations on a 2 × 2 table, as well as sum-
mary statistics with corresponding measures of variance. For con-
tinuous outcomes, we attempted to obtainmeans and standard de-
viations or data necessary to calculate this information. For time-
to-event outcomes, we attempted to obtain hazard ratios (HRs)
with corresponding measures of variance or data necessary to cal-
culate this information.
We resolved all disagreements by consensus.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents, or
multiple reports of a primary study, we maximised the yield of
information by mapping all publications to unique studies and
collating all available data. We used the most complete data set
aggregated across all known publications. In case of doubt, we
gave priority to the publication reporting the longest follow-up
associated with our primary or secondary outcomes.
Assessment of risk of bias in included studies
Two review authors (BR, OMA) independently assessed the risk
of bias of each included study and resolved all disagreements by
consensus.
We assessed risk of bias using Cochrane’s ‘Risk of bias’ assessment
tool for the following domains (Higgins 2011):
• Random sequence generation (selection bias)
• Allocation concealment (selection bias)
• Blinding of participants and personnel (performance bias)
• Blinding of outcome assessment (detection bias)
• Incomplete outcome data (attrition bias)
• Selective reporting (reporting bias)
• Other sources of bias
For detection bias, we evaluated the risk of bias separately for each
outcome. We regarded outcomes such as transfusion requirement
and hospital stay as objective, and, if reported, we judged these
studies as low risk. If studies did not report these outcomes, we
judged them as unclear risk.
For attrition bias, we evaluated risk of bias separately for quality of
life. We combined the outcomes major and minor postoperative
complications, hospital stay, transfusion requirement, and positive
margin rates into a single group for attrition bias.
Measures of treatment effect
We used Review Manager 5 (RevMan 5) (RevMan) to analyse the
data. We expressed dichotomous outcomes as risk ratios (RRs)
with 95% confidence intervals (CIs). For time-to-event outcomes,
we calculated the hazard ratio with 95% CI. We expressed contin-
uous data as mean differences (MDs) or standardised mean dif-
ferences (SMDs) (if the same outcome was evaluated by different
tools) with 95% CIs.
Unit of analysis issues
Parallel-group designswere to be analysed. The unit of analysis was
the individual participant. In the event we identified trials with
more than two intervention groups for inclusion in the review,
we handled these in accordance with guidance provided in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Dealing with missing data
When data were missing, we contacted corresponding authors of
the trials (Bochner 2015; Nix 2010; Parekh 2013; Parekh 2018).
We had received no response from the corresponding authors of
individual trials at the time of submission of this review. We im-
puted missing standard deviations in accordance with guidance
provided in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). We imputed means and standard de-
viations frommedian and range in accordance with guidance pro-
vided in Hozo 2005.
Assessment of heterogeneity
In the event of excessive heterogeneity unexplained by subgroup
analyses, we did not report outcome results as the pooled effect
estimate in a meta-analysis.
We identified heterogeneity by using a Chi² test on N-1 degrees
of freedom, with an alpha of 0.05 for statistical significance, and
using the I² statistic (Higgins 2003).We interpreted the I² statistic
as follows:
• 0% to 40%: may not be important
• 30% to 60%: may indicate moderate heterogeneity
• 50% to 90%: may indicate substantial heterogeneity
• 75% to 100%: indicates considerable heterogeneity
Assessment of reporting biases
We planned to obtain study protocols to evaluate studies for re-
porting bias. We did not formally perform funnel plot analysis, as
the review included only five trials.
Data synthesis
We summarised data using a random-effects model. We inter-
preted random-effects meta-analyses with due consideration of the
whole distribution of effects. In addition, we performed statisti-
cal analyses according to the statistical guidelines provided in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
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2011). For dichotomous outcomes, we used the Mantel-Haen-
szel method; for continuous outcomes, we used the inverse vari-
ancemethod; and for time-to-event outcomes, we used the generic
inverse variance method. We used RevMan software to perform
analyses.
GRADE and ‘Summary of findings’ table
We presented the overall quality of evidence for each outcome
according to the GRADE approach, which takes into account
five criteria related not only to internal validity (risk of bias, in-
consistency, imprecision, publication bias), but also to external
validity, such as directness of results (Guyatt 2008). Two review
authors (BR, OMA) independently rated the quality of evidence
for each outcome as ‘high’, ‘moderate’, ‘low’, or ‘very low’, using
GRADEpro GDT. We resolved any discrepancies by consensus.
We presented a summary of evidence for the main outcomes in
a ‘Summary of findings’ table, which provides key information
about the best estimate of the magnitude of effect in relative terms
and absolute differences for each relevant comparison of alterna-
tive management strategies; numbers of participants and studies
addressing each important outcome; and the rating of overall con-
fidence in effect estimates for each outcome (Guyatt 2011).
Main outcomes for ‘Summary of findings’ table
We have presented a ‘Summary of findings’ table to report the
following outcomes listed according to priority:
• Time to recurrence
• Major postoperative complications (class III to V) (Dindo
2004)
• Minor postoperative complications (class I and II) (Dindo
2004)
• Length of hospital stay (days)
• Quality of life
• Positive margins (%)
Subgroup analysis and investigation of heterogeneity
We attempted to perform subgroup analyses to explore possible
sources of heterogeneity. We considered the following subgroups:
• Participant age (younger than 60 years vs 60 years of age
and older)
• Participant body mass index (< 30 kg/m² vs ≥ 30 kg/m²)
• Pathological stage (≤ pT2 disease vs pT3 disease)
• Surgeon’s level of experience (less than expert vs expert, as
defined by trial authors)
We planned to test for subgroup differences using RevMan 5
to compare subgroup analyses if we found sufficient studies
(RevMan). We could not do this with the information provided
in the included studies.
R E S U L T S
Description of studies
We identified 332 references through electronic searches of the
different databases.
We retrieved a total of 32 references for further detailed as-
sessment. We excluded 26 references for the reasons listed in
the Characteristics of excluded studies table. We found that
seven references on five randomised controlled trials (RCTs) ful-
filled the review inclusion criteria (see Characteristics of included
studies). Two trials published outcomes in two separate publica-
tions (Bochner 2015; Parekh 2013). We have presented the refer-
ence flow in Figure 1 .
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Figure 1. Study flow diagram.
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Included studies
Study design and setting
Five trials were published between 2010 and 2018:
• Nix 2010 reported the first trial of RARC versus ORC.
Researchers conducted this study at the University of North
Carolina in the USA and randomised 21 participants to an open
approach and 20 to a robotic-assisted laparoscopic approach.
The study had a noninferiority design, and its primary outcome
was lymph node yield.
• The RAZOR trial (a prospective, multicentre, randomised
trial of open vs robotic radical cystectomy) was the largest and
most recently published trial (Parekh 2018). It was conducted at
15 academic centres in the USA and randomised 159 and 153
participants to RARC and ORC cohorts, respectively (Parekh
2018). After exclusions, 150 participants were included in the
RARC cohort and 152 participants in the ORC cohort, in the
per-protocol analysis set (Parekh 2018). The study used a
noninferiority design and included a primary outcome of
progression-free survival at two years.
• Parekh 2013 reported the results of a preceding pilot trial
leading up to the RAZOR trial that was conducted at the
University of Texas at San Antonio in the USA. Study authors
randomised 20 participants each to RARC and ORC and
reported oncological outcomes and quality of life outcomes - in
two separate publications (Parekh 2013). This study had no
specific primary endpoint aside from establishing randomisation.
• Bochner 2015 reported the results of a single-institution,
randomised trial conducted at Memorial Sloan Kettering Cancer
Center in the USA. Investigators randomised 60 and 58
participants to RARC and ORC cohorts, respectively. The study
was described as an expertise-based trial. Study authors reported
oncological outcomes in a second publication.
• Khan 2016 reported the results of a single-institution,
three-armed, randomised trial conducted at Guy’s Hospital, in
London, United Kingdom, that randomised 20 participants each
to RARC, ORC, and (pure) laparoscopic cystectomy. This study
was described as an expertise-based trial.
Participants
The total numbers of participants included in the ORC and
RARC cohorts were 270 and 271, respectively. Most participants
in both the ORC (221; 82%) and RARC (226; 83.4%) groups
weremen. Three studies reported demographic data using theme-
dian (Bochner 2015; Parekh 2013; Parekh 2018) and two using
the mean (Khan 2016; Nix 2010). The mean age of participants
in theORC cohort ranged between 66.6 years and 69.2 years. The
mean age of participants in the RARC cohort ranged between 67.4
years and 68.6 years. The median age of participants in the ORC
cohort ranged between 64.5 years and 65 years. The median age
of participants in the RARC cohort ranged between 66 years and
69.5 years. The mean body mass index (BMI) (in kg/m²) of par-
ticipants in the ORC cohort ranged between 27.4 and 28.4. The
mean BMI (kg/m²) of participants in the RARC cohort ranged
were similar at 27.5. The median BMI (kg/m²) of participants in
the ORC cohort ranged between 24.9 and 31.7, and the median
BMI (kg/m²) of participants in the RARC cohort ranged between
25 and 30.8.
Interventions and comparators
All five studies compared ORC to RARC (Bochner 2015; Khan
2016; Nix 2010; Parekh 2013; Parekh 2018); one trial included an
arm of laparoscopic radical cystectomy (Khan 2016). Four stud-
ies performed urinary diversion extracorporeally (Bochner 2015;
Khan 2016; Nix 2010; Parekh 2018). One study performed uri-
nary diversion at the discretion of the surgeon and did not ex-
plicitly report the type (Parekh 2013). In the ORC cohort, uri-
nary diversion was ileal conduit, neobladder, and continent cu-
taneous type in 194 (72%), 73 (27%), and 3 (1%) participants,
respectively. In the RARC cohort, urinary diversion was ileal con-
duit, neobladder, and continent cutaneous type in 191 (70.6%),
79 (29%), and 1 (0.4%) participant, respectively. All five trials
performed a pelvic lymph node dissection (Bochner 2015; Khan
2016; Nix 2010; Parekh 2013; Parekh 2018). We have sum-
marised the inclusion criteria for each study in the Characteristics
of included studies table.
Outcomes
Bochner 2015 reported on patient-reported outcomes (PROs) of
quality of life (QoL) using the validated European Organisation
for Research and Treatment of Cancer (EORTC) Quality of Life
Questionnaire Core 30 (QLQ-C30) survey. Khan 2016 evaluated
QoL using the validated Functional Assessment of Cancer Ther-
apy -Bladder (FACT-Bl) scale v4 questionnaire. Parekh 2013 and
Parekh 2018 evaluatedQoL using the validated Functional Assess-
ment of Cancer Therapy -Vanderbilt Cystectomy Index (FACT-
VCI) questionnaire.
Funding
Parekh 2018 was funded by the National Institutes of Health Na-
tional Cancer Institute.
Bochner 2015 was supported by the Sidney Kimmel Center for
Prostate and Urologic Cancers at Memorial Sloan Kettering Can-
cer Center, Pin Down Bladder Cancer, and the Michael and Zena
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Wienerfor Therapeutics Program in Bladder Cancer. Study spon-
sors were involved in the design and conduct of the study; in col-
lection, analysis, management, and interpretation of the data; and
in preparation, review, and approval of the manuscript.
Khan 2016 was supported by the National Institute for Health
Research (NIHR) Biomedical Research Centre based at Guy’s and
St. Thomas’ NHS Foundation Trust and King’s College London.
Study authors acknowledge support from the NIHR Biomedical
Research Centre, the Medical Research Council Centre for Trans-
plantation, King’sHealth Partners, Guy’s and St. Thomas’ Charity,
the School of Surgery, the London Deanery, the Royal College of
Surgeons of England, Intuitive Surgical, the Urology Foundation,
Olympus, EU-FP7, ProstateCancer UK, the Technology Strategy
Board, and the Vattikuti Foundation.
The remaining two studies did not report funding (Nix 2010;
Parekh 2013).
Excluded studies
We excluded 26 of these publications. All of these studies were
nonrandomised comparative studies comparing ORC and RARC
(Excluded studies). We have documented further details of indi-
vidual studies in the Characteristics of excluded studies table.
Risk of bias in included studies
We have summarised the methodology and risk of bias of individ-
ual trials in the Characteristics of included studies table.
We have summarised the risk of bias for individual trials in Figure
2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Random sequence generation
We judged all five trials to have low risk of bias for random sequence
allocation (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013;
Parekh 2018).
Allocation concealment
Nix 2010 performed a randomisation schema with five sequen-
tial participants undergoing one approach before alternating with
another approach. Their concealment would have to be deemed
inadequate and hence judged to be at high risk of bias. The re-
maining trials had low risk of bias in their allocation concealment
strategy (Bochner 2015; Khan 2016; Parekh 2013; Parekh 2018).
Blinding
Performance bias
Due to the nature of the intervention (RARC vs ORC), it is con-
sidered unlikely that participants or personnel were blinded for
any of the review outcomes.We therefore judged all included stud-
ies to be at high risk of performance bias.
Detection bias
Time to recurrence
Two trials reported on recurrence-free survival (Bochner 2015;
Parekh 2018). Due to the lack of blinding of outcome assessors,
we judged Parekh 2018 to be at high risk of detection bias for
recurrence-free survival (Parekh 2018). We judged one trial as
having unclear risk of detection bias for recurrence-free survival,
as trial authors did not explicitly state who assessed this outcome
(Bochner 2015).
Complications (all grades)
Three included studies were unblinded; we therefore judged them
to be at high risk of detection bias for complications (Bochner
2015; Khan 2016; Parekh 2018). Two studies did not report who
the assessors were and whether blinding had taken place; hence
we judged them to be at unclear risk of detection bias for compli-
cations (Nix 2010; Parekh 2013).
Quality of life
In all four included studies, participants were not blinded; we
therefore judged these trials to be at high risk of detection bias for
the self-assessed outcome of quality of life survey (Bochner 2015;
Khan 2016; Parekh 2013; Parekh 2018).
One study did not report quality of life data (Nix 2010).
Positive margin rates, hospital stay, and transfusion rates
The review authors opined that positivemargin rates, hospital stay,
and transfusion rates were unlikely to be affected by the blinding
status of outcome assessors in these trials. We therefore judged all
five studies to be at low risk of detection bias for positive surgical
margin rates and hospital stay (Bochner 2015; Khan 2016; Nix
2010; Parekh 2013; Parekh 2018).
Nix 2010, Bochner 2015, and Khan 2016 did not report on trans-
fusion rates. We judged Parekh 2018 and Parekh 2013 to be at
low risk of detection bias for transfusion rates.
Incomplete outcome data
Quality of life
We judged four studies to be at high risk of attrition bias for quality
of life survey results, given that a large proportion of participants (>
20%) failed to provide information (Bochner 2015; Khan 2016;
Parekh 2013; Parekh 2018).
Major and minor postoperative complications, transfusion
requirements, hospital stay, and positive margins
We rated all studies as having low risk of attrition bias with near
complete inclusionof randomised participants in analyses for these
outcomes (Bochner 2015; Khan 2016; Nix 2010; Parekh 2013;
Parekh 2018).
Time to recurrrence
We rated Bochner 2015 as having low risk of attrition bias, with all
randomised participants included in the analysis. We rated Parekh
2018 as having unclear risk of attrition bias.
Selective reporting
Four studies had protocols registered in a trials registry (Bochner
2015; Khan 2016; Parekh 2013; Parekh 2018). We noted no ob-
vious selective reporting for the outcomes of this review in these
studies, and hence we judged them as having low risk of reporting
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bias. We were unable to find a protocol for the Nix 2010 trial.
Therefore, we judged this trial as having an unclear risk of report-
ing bias.
Other potential sources of bias
We identified no other biases in any of the other included trials (
Bochner 2015;Khan2016;Nix 2010; Parekh 2013; Parekh 2018).
Effects of interventions
See: Summary of findings for the main comparison Robotic-
assisted laparoscopic vs open radical cystectomy for bladder cancer
in adults
Primary outcomes
Time to recurrence
RARC may result in a similar time to recurrence as ORC (hazard
ratio (HR) 1.05, 95% confidence interval (CI) 0.77 to 1.43); 2
trials; low-certainty evidence) (Figure 3). We downgraded the cer-
tainty of evidence for study limitations and imprecision (Analysis
1.1; Summary of findings for the main comparison). In absolute
terms, this corresponds to 16 more recurrences per 1000 partici-
pants (95% CI 79 fewer to 123 more). The control event rate at
5 years was based on an overall recurrence rate of 25/58 (43.1%)
in the ORC arm reported in Bochner 2015.
Figure 3. Forest plot of comparison: 1 Primary Outcome, outcome: 1.1 Recurrence-Free Survival.
Major complications (Clavien grades 3 to 5)
RARC may result in similar rates of major complications as ORC
(risk ratio (RR) 1.06, 95% CI 0.76 to 1.48); 5 trials; low-certainty
evidence) (Figure 4). This corresponds to 11 more major com-
plications per 1000 participants (95% CI 44 fewer to 89 more).
We downgraded the certainty of evidence for study limitations
and imprecision (Analysis 1.2; Summary of findings for the main
comparison).
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Figure 4. Forest plot of comparison: 1 Primary outcome, outcome: 1.1 Major postoperative complication
rates (Clavien 3 to 5).
Five trials reported on complications. Three studies reported the
total number of Clavien grade 3 to 5 complications (Bochner
2015; Khan 2016; Parekh 2018). The other two studies reported
specific complications (Nix 2010; Parekh 2013), based on which
the review authors were able to classify complications by adopting
the Clavien-Dindo grading system (Dindo 2004).
Secondary outcomes
Minor complications (Clavien grades 1 and 2)
We are very uncertain whether RARC results in fewer minor com-
plications than ORC (RR 0.82, 95% CI 0.58 to 1.17; 4 trials;
very low-certainty evidence). This corresponds to 80 fewer minor
complications per 1000 participants (95% CI 186 fewer to 75
more). We downgraded the certainty of evidence for serious study
limitations and very serious imprecision (Analysis 1.3; Summary
of findings for the main comparison).
Transfusion rate
RARC probably results in fewer transfusions thanORC (RR 0.58,
95% CI 0.43 to 0.80; 2 trials; moderate-certainty evidence). This
corresponds to 193 fewer transfusions per 1000 participants (95%
CI 262 fewer to 92 fewer). We downgraded the certainty of evi-
dence for study limitations (Analysis 1.4; Summary of findings for
the main comparison). Only two studies reported on transfusion
rates (Parekh 2013; Parekh 2018).
Length of hospital stay (days)
All five trials provided information on hospital stay. One trial
reported similar mean hospital stays of 5.1 days and 6 days in the
RARC and ORC cohorts but did not report a standard deviation
(Nix 2010). We therefore imputed the standard deviation. Two
trials reported hospital stay in median and range values (Parekh
2013; Parekh 2018).We therefore imputed themean and standard
deviation for these trials. Two studies provided explicit data on
mean hospital stay for meta-analysis (Bochner 2015; Khan 2016).
Overall, we found that RARC may reduce mean hospital stay
slightly (mean difference (MD) -0.67, 95% CI -1.22 to -0.12;
5 trials; low-certainty evidence). We downgraded the quality of
evidence for study limitations and imprecision (Analysis 1.5;
Summary of findings for the main comparison).
Quality of life
RARC may result in similar quality of life when compared with
ORC (standardmean difference (SMD) 0.08, 95%CI: 0.32 lower
to 0.16 higher; 3 trials; low-certainty evidence). We downgraded
the certainty of evidence for study limitations and imprecision
(Analysis 1.6; Summary of findings for the main comparison).
Four studies reported on quality of life (QoL) outcomes (Bochner
2015; Khan 2016; Parekh 2013; Parekh 2018). One trial used
the European Organisation for Research and Treatment of Can-
cer (EORTC)Quality of Life Questionnaire Core 30 (QLQ-C30)
survey (Bochner 2015). In this trial, data from the Global Health
status domain were used for analysis, as this information reflected
overall health status. One trial used the Functional Assessment of
Cancer Therapy -Bladder (FACT-Bl) scale v4 and covered phys-
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ical, emotional, and social well-being, as well as questions spe-
cific to bladder cancer (Khan 2016). Two trials used the Func-
tional Assessment of Cancer Therapy -Vanderbilt Cystectomy In-
dex (FACT-VCI) questionnaire (Parekh 2013; Parekh 2018). The
standardised mean difference was used in view of the different
QoL assessment tools used. One study reported QoL in median
and range values (Parekh 2013). We therefore imputed mean and
standard deviation for this study.
Positive margin rates
RARC may result in similar positive margin rates when compared
to ORC (RR 1.16, 95% CI 0.56 to 2.40; 5 trials; low-certainty
evidence). This corresponds to eight more positive margins per
1000 participants (95% CI 21 fewer to 67 more).
We downgraded the certainty of evidence for study limitations
and imprecision (Analysis 1.7; Summary of findings for the main
comparison).
We were unable to conduct any of the preplanned secondary anal-
yses due to lack of suitable data.
D I S C U S S I O N
Summary of main results
There may be little to no difference in time to recurrence and in
risk of major complications between the two surgical approaches
to treat muscle-invasive bladder cancer. We are very uncertain
whether RARC reduces the rate of minor complications. There
may be little to no difference in quality of life and positive margin
rates. RARC probably reduces transfusions substantially and may
reduce length of stay slightly.
Overall completeness and applicability of
evidence
Follow-up of the included trials is generally limited; only one trial
has reported longer-term follow-up for the outcome of recurrence-
free survival at a median follow-up of 4.9 years (Bochner 2015).
Another trial reported on progression-free survival at two years
(Parekh 2018). Review authors judged this trial to have high risk of
performance and detection bias for recurrence-free survival. One
small trial provided data on recurrence rates and overall and dis-
ease-specific mortality at 12 months (Khan 2016). We judged this
trial to have high risk of performance, detection, attrition, and re-
porting bias. Follow-up was very short, at 12 months, further em-
phasising the lack of vital long-term oncological data derived from
randomised controlled trials (RCTs) comparing open radical cys-
tectomy (ORC) and robotic-assisted radical cystectomy (RARC).
All studies reported on complication rates. However, two studies
did not demonstrate clear categorisation into minor and major
complications using the Clavien-Dindo grading system, as sug-
gested by this review (Nix 2010; Parekh 2013). We therefore ex-
amined individual complications reported by these trials and clas-
sified them using the Clavien-Dindo grading system. Although
data show no obvious differences between ORC and RARC for
major complications, the outcomes again were of low quality, sug-
gesting significant uncertainty of the results, and hence must be
viewed with caution.
For the outcomes “hospital stay” and “quality of life”, three studies
reported unfavourable metrics and statistical methods (e.g. me-
dian, no standard deviations reported for means) for meta-anal-
ysis (Nix 2010; Parekh 2013, Parekh 2018). The review authors
therefore imputed these data.
Quality of the evidence
We rated the certainty of evidence as low for all outcomes, except
transfusion rates and hospital stay. We consistently downgraded
evidence for a combination of study limitations, most often per-
formance bias (lack of blinding of participants and personnel) and
detection bias (lack of blinding of outcome assessors). We also fre-
quently downgraded evidence for imprecision due to wide confi-
dence intervals that indicated no effect but also included the pos-
sibility of clinically relevant benefit or harm.
Potential biases in the review process
We performed this systematic review in accordance with current
Cochrane standards. The review nevertheless has the following
limitations:
• The review authors cannot be absolutely certain if we
missed identifying any other potential randomised trials
comparing ORC and RARC in our search, although we think
this is unlikely.
• We excluded from the meta-analysis some of the data
reported by individual studies due to lack of appropriate data
points. We contacted the authors of these individual studies but
were not successful in obtaining additional data. We chose to
impute data in accordance with the editorial policy of Cochrane
standards.
Agreements and disagreements with other
studies or reviews
We identified five relevant systematic reviews of randomised and
nonrandomised controlled trials comparing robotic and open rad-
ical cystectomy (Ishii 2014; Novara 2015; Tang 2014; Yuh 2015;
Sathianathen 2018). These reviews used pooled data derived across
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all study designs, and none considered evaluation of the quality of
evidence as defined by GRADE.
Yuh 2015 performed a cumulative analysis of oncological
and functional outcomes of robotic-assisted radical cystectomy
(RARC). This review identified 65 surgical series and 22 compara-
tive studies reporting on pathological, oncological, and functional
outcomes of RARC. Two trials in the review were randomised tri-
als (Nix 2010; Parekh 2013). We included both of these studies in
our review. A majority of the studies included in this review were
retrospective studies. No certainty of evidence was assessed. The
review identified two nonrandomised comparative studies that re-
ported similar survival outcomes betweenORC and RARC (Khan
2012; Nepple 2013). Review authors suggested caution when in-
terpreting these results due to short follow-up, small series, and
study limitations.
Novara 2015 performed a cumulative analysis of perioperative
outcomes and postoperative complications of RARC. This review
identified 70 surgical series and 23 comparative studies. Three tri-
als included in the review were randomised trials (Bochner 2015;
Nix 2010; Parekh 2013). We have included these three studies in
our review. A majority of studies included in the Novara review
were retrospective studies. Review authors categorised individual
studies to the 2011 level of evidence and IDEAL recommenda-
tions and scrutinised the quality of reporting of complications of
individual studies using the Martin criteria (Martin 2002). They
performed no other quality assessment of individual studies. These
review authors reported 90-day complication rates of any grade
and found that 90-day grade 3 complication rates were lower for
RARC, whereas high-grade complication and mortality rates were
similar. It is unclear from the review how the review authors differ-
entiated between grade 3 complications and high-grade complica-
tions. The analysis for grade 3 complications did not include any
of the RCTs. The analysis for high-grade complications included
one RCT (Bochner 2015). The RCT included in this analysis con-
tributed 19.3% to the study weight.
Tang 2014 performed a systematic review that included 13 stud-
ies comparing RARC and ORC. One trial in the review was a
randomised trial (Nix 2010). We have included this study in our
review. These review authors reported perioperative and patho-
logical outcomes and complications. Review authors pooled data
across all study designs. They rated the level of evidence (LOE) of
included studies according to criteria provided by the Centre for
Evidence-Based Medicine in Oxford, UK. They assessed risk of
bias of the RCT using the Jadad scale and of observational studies
using the Newcastle-Ottawa scale. Pooled analysis favoured the
RARC cohort for overall complication rate. Nix 2010, the only
RCT included in the analysis, contributed only 5.5% to the study
weight.
Ishii 2014 performed a systematic review that included seven stud-
ies comparing RARC and ORC. Two trials in the review were
randomised trials (Nix 2010; Parekh 2013). We have included
both of these studies in our review. Review authors assessed the
methodological quality of these included studies in line with the
Cochrane Handbook for Systematic Reviews of Interventions. The pri-
mary outcome of this study was complication rates. Pooled analy-
sis favoured the RARC cohort for major complication rates. Anal-
ysis for major complications included one RCT (Parekh 2013),
which contributed to 6.7% to the study weight.
Sathianathen 2018 has published the most recent and highest-
quality review to date. Methodolgical hallmarks include an a pri-
ori registered protocol with predefined primary outcomes, a com-
prehensive search of multiple data sources, and study inclusion
irrespective of language of publication status and use of GRADE
to assess the quality of evidence on a per-outcome basis. Instead of
recurrence-free survival as a time-to-event outcome used in our re-
view, these review authors analysed risk of recurrence as a dichoto-
mous outcome. They rated findings as moderate-quality evidence,
which is more optimistic than our rating of low-quality evidence,
while qualifying that there is little to no difference between the
two approaches. What our review further adds is a summary of
findings table (Summary of findings for the main comparison)
with corresponding absolute effect size estimates.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the findings of this review, oncological outcomes and
rates of major complications may be similar for both approaches.
Robotic-assisted cystectomy probably reduces transfusion needs
substantially andmay slightly reduce length of hospital stay.We are
uncertain whether minor complications are also reduced.We were
unable to address how patients’ and surgeons’ characteristics may
affect these outcomes. Furthermore, this review was not designed
to address resource utilisation or cost-effectiveness.
Implications for research
This review is based on five relatively small trials with method-
ological limitations that provided low-quality evidence for most
outcomes. Only one trial has provided long-term oncological out-
comes (Bochner 2015). We see the following research needs:
• Investigators of existing trials should report longer-term
results for longer-term oncological outcomes.
• Researchers should assess the influence of patient factors
such as pathological stage and body habitus.
• Studies should establish the impact of surgeon factors such
as skills and experience on outcomes.
• Most instances of urinary diversion reported in included
trials were performed through an extracorporeal approach.
Future trials should evaluate outcomes between open radical
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cystectomy and robotic-assisted radical cystectomy performed
through intracorporeal urinary diversions.
• Any future trial should apply widely accepted
methodological safeguards against bias and should transparently
report them.
A C K N OW L E D G E M E N T S
We would like to thank the editors of Cochrane Urology for the
support they provided.
R E F E R E N C E S
References to studies included in this review
Bochner 2015 {published data only}
Bochner BH, Dalbagni G, Marzouk KH, Sjoberg DD, Lee
J, Donat SM, et al. Randomized trial comparing open
radical cystectomy and robot-assisted laparoscopic radical
cystectomy: oncologic outcomes. European Urology 2018;
74(4):465–71. PUBMED: 29784190]
Bochner BH, Dalbagni G, Sjoberg DD, Silberstein J,
Keren Paz GE, Donat SM, et al. Comparing open
radical cystectomy and robot-assisted laparoscopic radical
cystectomy: a randomized clinical trial. European Urology
2015;67(6):1042–50.
Khan 2016 {published data only}
Khan MS, Gan C, Ahmed K, Ismail AF, Watkins J,
Summers JA, et al. A single-centre early phase randomised
controlled three-arm trial of open, robotic, and laparoscopic
radical cystectomy (CORAL). European Urology 2016;69
(4):613–21.
Nix 2010 {published data only}
Nix J, Smith A, Kurpad R, Nielsen ME, Wallen EM, Pruthi
RS. Prospective randomized controlled trial of robotic versus
open radical cystectomy for bladder cancer: perioperative
and pathologic results. European Urology 2010;57(2):
196–201.
Parekh 2013 {published data only}
Messer JC, Punnen S, Fitzgerald J, Svatek R, Parekh DJ.
Health-related quality of life from a prospective randomised
clinical trial of robot-assisted laparoscopic versus open
radical cystectomy. BJU International 2014;114(6):
896–902.
Parekh DJ, Messer J, Fitzgerald J, Ercole B, Svatek R.
Perioperative outcomes and oncologic efficacy from a pilot
prospective randomized clinical trial of open versus robotic
assisted radical cystectomy. Journal of Urology 2013;189(2):
474–9.
Parekh 2018 {published data only}
∗ Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods
ME, Svatek RS, et al. Robot-assisted radical cystectomy
versus open radical cystectomy in patients with bladder
cancer (RAZOR): an open-label, randomised, phase 3, non-
inferiority trial. Lancet 2018;391:2525–36.
References to studies excluded from this review
Anderson 2013 {published data only}
Anderson CB, Morgan TM, Kappa S, Moore D, Clark
PE, Davis R, et al. Ureteroenteric anastomotic strictures
after radical cystectomy - does operative approach matter?.
Journal of Urology 2013;189(2):541–7.
Atmaca 2015 {published data only}
Atmaca AF, Canda AE, Gok B, Akbulut Z, Altinova S,
Balbay MD. Open versus robotic radical cystectomy with
intracorporeal Studer diversion. Journal of the Society
of Laparoendoscopic Surgeons 2015;19(1):e2014.00193.
PUBMED: 25848187]
Bak 2016 {published data only}
Bak DJ, Lee YJ, Woo MJ, Chung JW, Ha YS, Kim HT,
et al. Complications and oncologic outcomes following
robot-assisted radical cystectomy: what is the real benefit?
. Investigative and Clinical Urology 2016;57(4):260–7.
PUBMED: 27437535]
Borza 2017 {published data only}
Borza T, Jacobs BL, Montgomery JS, Weizer AZ, Morgan
TM, Hafez KS, et al. No differences in population-
based readmissions after open and robotic-assisted radical
cystectomy: implications for post-discharge care. Urology
2017;104:77–83. PUBMED: 28267606]
Cusano 2016 {published data only}
Cusano A, Haddock P Jr, Jackson M, Staff I, Wagner
J, Meraney A. A comparison of preliminary oncologic
outcome and postoperative complications between patients
undergoing either open or robotic radical cystectomy.
International Brazilian Journal of Urology 2016;42(4):
663–70. PUBMED: 27564275]
Galich 2006 {published data only}
Galich A, Sterrett S, Nazemi T, Pohlman G, Smith L, Balaji
KC. Comparative analysis of early perioperative outcomes
19Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
following radical cystectomy by either the robotic or open
method. Journal of the Society of Laparoendoscopic Surgeons
2006;10(2):145–50.
Gandaglia 2016 {published data only}
Gandaglia G, Karl A, Novara G, de Groote R, Buchner A,
D’Hondt F, et al. Perioperative and oncologic outcomes of
robot-assisted versus open radical cystectomy in bladder
cancer patients: a comparison of two high-volume referral
centers. European Journal of Surgical Oncology 2016;42(11):
1736–43. PUBMED: 27032295]
Ginot 2016 {published data only}
Ginot R, Rouget B, Bensadoun H, Pasticier G, Bernhard
JC, Capon G, et al. Radical cystectomy with orthotopic
neobladder replacement: comparison of robotic assisted and
open surgical route [Cystectomie totale avec remplacement
vesical orthotopique: comparaison des resultats des
patients operes par voie ouverte et par voie coelioscopique
robot–assistee.]. Progres en Urologie 2016;26(8):457–63.
PUBMED: 27460787]
Gondo 2012 {published data only}
Gondo T, Yoshioka K, Nakagami Y, Okubo H, Hashimoto
T, Satake N, et al. Robotic versus open radical cystectomy:
prospective comparison of perioperative and pathologic
outcomes in Japan. Japanese Journal of Clinical Oncology
2012;42(7):625–31.
Khan 2012 {published data only}
Khan MS, Challacombe B, Elhage O, Rimington P, Coker
B, Murphy D, et al. A dual-centre, cohort comparison of
open, laparoscopic and robotic-assisted radical cystectomy.
International Journal of Clinical Practice 2012;66(7):
656–62.
Koupparis 2015 {published data only}
Koupparis A, Villeda-Sandoval C, Weale N, El-Mahdy M,
Gillatt D, Rowe E. Robot-assisted radical cystectomy with
intracorporeal urinary diversion: impact on an established
enhanced recovery protocol. BJU International 2015;116
(6):924–31. PUBMED: 25943158]
Lee 2011 {published data only}
Lee R, Ng CK, Shariat SF, Borkina A, Guimento R,
Brumit KF, et al. The economics of robotic cystectomy:
cost comparison of open versus robotic cystectomy. BJU
International 2011;108(11):1886–92.
Li 2016 {published data only}
Li AY, Filson CP, Hollingsworth JM, He C, Weizer AZ,
Hollenbeck BK, et al. Patient-reported convalescence and
quality of life recovery: a comparison of open and robotic-
assisted radical cystectomy. Surgical Innovation 2016;23(6):
598–605. PUBMED: 27354552]
Martin 2011 {published data only}
Martin AD, Nunez RN, Castle EP. Robot-assisted radical
cystectomy versus open radical cystectomy: a complete cost
analysis. Urology 2011;77(3):621–5.
Matulewicz 2016 {published data only}
Matulewicz RS, DeLancey JO, Manjunath A, Tse J,
Kundu SD, Meeks JJ. National comparison of oncologic
quality indicators between open and robotic-assisted
radical cystectomy. Urologic Oncology 2016;34(10):
431.e9–431.e15. PUBMED: 27264169]
Musch 2014 {published data only}
Musch M, Janowski M, Steves A, Roggenbuck U, Boergers
A, Davoudi Y, et al. Comparison of early postoperative
morbidity after robot-assisted and open radical cystectomy:
results of a prospective observational study. BJU
international 2014;113(3):458–67.
Nepple 2013 {published data only}
Nepple KG, Strope SA, Grubb RL 3rd, Kibel AS.
Early oncologic outcomes of robotic versus open radical
cystectomy for urothelial cancer. Urologic Oncology 2013;31
(6):894–8. PUBMED: 21803615]
Ng 2010 {published data only}
Ng CK, Kauffman EC, Lee MM, Otto BJ, Portnoff
A, Ehrlich JR, et al. A comparison of postoperative
complications in open versus robotic cystectomy. European
Urology 2010;57(2):274–82.
Nguyen 2015 {published data only}
Nguyen DP, Al Hussein Al Awamlh B, Wu X, O’Malley P,
Inoyatov IM, Ayangbesan A, et al. Recurrence patterns
after open and robot-assisted radical cystectomy for bladder
cancer. European Urology 2015;68(3):399–405. PUBMED:
25709026]
Rhee 2006 {published data only}
Rhee JJ, Lebeau S, Smolkin M, Theodorescu D. Radical
cystectomy with ileal conduit diversion: early prospective
evaluation of the impact of robotic assistance. BJU
International 2006;98(5):1059–63.
Satkunasivam 2016 {published data only}
Satkunasivam R, Santomauro M, Chopra S, Plotner E, Cai
J, Miranda G, et al. Robotic intracorporeal orthotopic
neobladder: urodynamic outcomes, urinary function, and
health-related quality of life. European Urology 2016;69(2):
247–53. PUBMED: 26164417]
Sharma 2017 {published data only}
Sharma P, Zargar-Shoshtari K, Poch MA, Pow-Sang JM,
Sexton WJ, Spiess PE, et al. Surgical control and margin
status after robotic and open cystectomy in high-risk cases:
caution or equivalence?. World Journal of Urology 2017;35
(4):657–63. PUBMED: 27495912]
Styn 2012 {published data only}
Styn NR, Montgomery JS, Wood DP, Hafez KS, Lee CT,
Tallman C, et al. Matched comparison of robotic-assisted
and open radical cystectomy. Urology 2012;79(6):1303–9.
Tan 2016 {published data only}
Tan WS, Sridhar A, Ellis G, Lamb B, Goldstraw M, Nathan
S, et al. Analysis of open and intracorporeal robotic
assisted radical cystectomy shows no significant difference
in recurrence patterns and oncological outcomes. Urologic
Oncology 2016;34(6):257.e1–9. PUBMED: 26968561]
Wang 2008 {published data only}
Wang GJ, Barocas DA, Raman JD, Scherr DS. Robotic
vs open radical cystectomy: prospective comparison of
perioperative outcomes and pathological measures of early
oncological efficacy. BJU International 2008;101(1):89–93.
20Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Winters 2016 {published data only}
Winters BR, Bremjit PJ, Gore JL, Lin DW, Ellis WJ, Dalkin
BL, et al. Preliminary comparative effectiveness of robotic
versus open radical cystectomy in elderly patients. Journal
of Endourology 2016;30(2):212–7. PUBMED: 26414964]
References to ongoing studies
Kelly , Catto 2017 {published data only}
Kelly J, Catto J. Trial to compare robotically assisted radical
cystectomy with open radical cystectomy (iROC). https://
clinicaltrials.gov/ct2/show/NCT03049410 (accessed 7 June
2017).
Additional references
Aboumarzouk 2012
Aboumarzouk OM, Drewa T, Olejniczak P, Chlosta PL.
Laparoscopic radical cystectomy: a 5-year review of a single
institute’s operative data and complications and a systematic
review of the literature. International Brazilian Journal of
Urology 2012;38(3):330–40.
Aboumarzouk 2013
Aboumarzouk OM, Hughes O, Narahari K, Drewa
T, Chlosta PL, Kynaston H. Safety and feasibility of
laparoscopic radical cystectomy for the treatment of bladder
cancer. Journal of Endourology / Endourological Society 2013;
27(9):1083–95.
Ballantyne 2003
Ballantyne GH, Moll F. The da Vinci telerobotic surgical
system: the virtual operative field and telepresence surgery.
Surgical Clinics of North America 2003;83(6):1293-304, vii.
Castillo 2006
Castillo OA, Abreu SC, Mariano MB, Tefilli MV, Hoyos
J, Pinto I, et al. Complications in laparoscopic radical
cystectomy: the South American experience with 59 cases.
International Brazilian Journal of Urology 2006;32(3):
300–5.
Castillo 2009
Castillo OA, Vitagliano G, Vidal-Mora I. Laparoscopic
radical cystectomy: the new gold standard for bladder
carcinoma?. Archivos Espanoles de Urologia 2009;62(9):
737–44.
Cathelineau 2005
Cathelineau X, Arroyo C, Rozet F, Barret E, Vallancien G.
Laparoscopic assisted radical cystectomy: the Montsouris
experience after 84 cases. European Urology 2005;47(6):
780–4.
Dindo 2004
Dindo D, Demartines N, Clavien PA. Classification of
surgical complications: a new proposal with evaluation in a
cohort of 6336 patients and results of a survey. Annals of
Surgery 2004;240(2):205–13.
Ferlay 2013
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser
S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer
Incidence and Mortality Worldwide: IARC CancerBase
No. 11. Lyon, France: International Agency for Research
on Cancer; 2013. globocan.iarc.fr (accessed 5 June 2015).
Ferlay 2015
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C,
Rebelo M, et al. Cancer incidence and mortality worldwide:
sources, methods and major patterns in GLOBOCAN
2012. International Journal of Cancer 2015;136(5):
E359–86.
GRADEpro GDT
GRADEpro GDT: GRADEpro Guideline Development
Tool [Software]. Hamilton (ON): McMaster University,
2015 (developed by Evidence Prime, Inc.). Available from
www.gradepro.org.
Guyatt 2008
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter
Y, Schünemann HJ, et al. GRADE: what is “quality of
evidence” and why is it important to clinicians?. BMJ
(Clinical Research Ed) 2008;336(7651):995–8. DOI:
10.1136/bmj.39490.551019.BE
Guyatt 2011
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek
J, et al. GRADE guidelines: 1. Introduction - GRADE
evidence profiles and summary of findings tables. Journal of
Clinical Epidemiology 2011;64(4):383–94. DOI: 10.1016/
j.jclinepi.2010.04.026
Haber 2008
Haber GP, Crouzet S, Gill IS. Laparoscopic and robotic
assisted radical cystectomy for bladder cancer: a critical
analysis. European Urology 2008;54(1):54–62.
Hayn 2010
Hayn MH, Hussain A, Mansour AM, Andrews PE,
Carpentier P, Castle E, et al. The learning curve of robot-
assisted radical cystectomy: results from the International
Robotic Cystectomy Consortium. European Urology 2010;
58(2):197–202.
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analyses. BMJ (Clinical
Research Ed.) 2003;327(7414):557–60. MEDLINE:
12958120
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions. Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Hosseini 2011
Hosseini A, Adding C, Nilsson A, Jonsson MN, Wiklund
NP. Robotic cystectomy: surgical technique. BJU
International 2011;108(6b):962–8.
Hozo 2005
Hozo SP, Djulbegovic B, Hozo I. Estimating the mean
and variance from the median, range, and the size of a
sample. BMC Medical Research Methodology 2005;5:13.
[PUBMED: 15840177]
21Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hu 2009
Hu JC, Gu X, Lipsitz SR, Barry MJ, D’Amico AV,Weinberg
AC, et al. Comparative effectiveness of minimally invasive
versus open radical prostatectomy. JAMA 2009;302(14):
1557–64. [PUBMED: 19826025]
Huang 2008
Huang J, Lin T, Xu K, Huang H, Jiang C, Han J, et al.
Laparoscopic radical cystectomy with orthotopic ileal
neobladder: a report of 85 cases. Journal of Endourology /
Endourological Society 2008;22(5):939–46.
Huang 2010
Huang J, Lin T, Liu H, Xu K, Zhang C, Jiang C, et al.
Laparoscopic radical cystectomy with orthotopic ileal
neobladder for bladder cancer: oncologic results of 171
cases with a median 3-year follow-up. European Urology
2010;58(3):442–9.
Ishii 2014
Ishii H, Rai BP, Stolzenburg JU, Bose P, Chlosta PL, Somani
BK, et al. Robotic or open radical cystectomy, which is
safer? A systematic review and meta-analysis of comparative
studies. Journal of Endourology / Endourological Society 2014;
28(10):1215–23. [PUBMED: 25000311]
Jonsson 2011
Jonsson MN, Adding LC, Hosseini A, Schumacher MC,
Volz D, Nilsson A, et al. Robot-assisted radical cystectomy
with intracorporeal urinary diversion in patients with
transitional cell carcinoma of the bladder. European Urology
2011;60(5):1066–73.
Khan 2011
Khan MS, Elhage O, Challacombe B, Rimington P, Murphy
D, Dasgupta P. Analysis of early complications of robotic-
assisted radical cystectomy using a standardized reporting
system. Urology 2011;77(2):357–62.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche
PC, Ioannidis JPA, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies
that evaluate health care interventions: explanation and
elaboration. PLoS Medicine 2009;6(7):e1000100. DOI:
10.1371/journal.pmed.1000100
Martin 2002
Martin RC 2nd, Brennan MF, Jaques DP. Quality of
complication reporting in the surgical literature. Annals of
Surgery 2002;235(6):803–13. [PUBMED: 12035036]
Novara 2012
Novara G, Ficarra V, Rosen RC, Artibani W, Costello A,
Eastham JA, et al. Systematic review and meta-analysis
of perioperative outcomes and complications after robot-
assisted radical prostatectomy. European Urology 2012;62
(3):431–52.
Novara 2015
Novara G, Catto JW, Wilson T, Annerstedt M, Chan K,
Murphy DG, et al. Systematic review and cumulative
analysis of perioperative outcomes and complications after
robot-assisted radical cystectomy. European Urology 2015;
67(3):376–401.
Ploeg 2009
Ploeg M, Aben KK, Kiemeney LA. The present and future
burden of urinary bladder cancer in the world. World
Journal of Urology 2009;27(3):289–93.
Raza 2015
Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS,
Al-Daghmin A, et al. Long-term oncologic outcomes
following robot-assisted radical cystectomy: results from the
International Robotic Cystectomy Consortium. European
Urology 2015;68(4):721–8. [PUBMED: 25985883]
Redorta 2010
Redorta JP, Gaya JM, Breda A, Gausa L, Rodríguez
O, Villavicencio H. Robotic cystectomy versus open
cystectomy: are we there yet?. European Urology Supplements
2010;9(3):433–7.
RevMan [Computer program]
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
The Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Sathianathen 2018
Sathianathen NJ, Kalapara A, Frydenberg M, Lawrentschuk
N, Weight, C, Parek D, Konety BR. Robotic-assisted radical
cystectomy vs open radical cystectomy: systematic review
and meta-analysis. Journal of Urology 2018/10/16;201(4):
715–720. [PUBMED: 30321551]
Schwenk 2005
Schwenk W, Haase O, Neudecker J, Muller JM. Short term
benefits for laparoscopic colorectal resection. Cochrane
Database of Systematic Reviews 2005;3:CD003145.
[PUBMED: 16034888]
Shabsigh 2009
Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin
AM, Savage C, et al. Defining early morbidity of radical
cystectomy for patients with bladder cancer using a
standardized reporting methodology. European urology
2009;55(1):164–74. [PUBMED: 18675501]
Sighinolfi 2007
Sighinolfi MC, Micali S, Celia A, DeStefani S, Grande M,
Rivalta M, et al. Laparoscopic radical cystectomy: an Italian
survey. Surgical Endoscopy 2007;21(8):1308–11.
Smith 2011
Smith AB, Raynor MC, Pruthi RS. Peri- and postoperative
outcomes of robot-assisted radical cystectomy (RARC). BJU
International 2011;108(6 Pt 2):969–75.
Tang 2014
Tang K, Xia D, Li H, Guan W, Guo X, Hu Z, et al. Robotic
vs. open radical cystectomy in bladder cancer: a systematic
review and meta-analysis. European Journal of Surgical
Oncology 2014;40(11):1399–411. [PUBMED: 24767803]
Witjes 2014
Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis
G, Lebret T, et al. EAU guidelines on muscle-invasive and
22Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
metastatic bladder cancer: summary of the 2013 guidelines.
European Urology 2014;65(4):778–92. [PUBMED:
24373477]
Wright 2013
Wright JD, Ananth CV, Lewin SN, Burke WM, Lu YS,
Neugut AI, et al. Robotically assisted versus laparoscopic
hysterectomy among women with benign gynecologic
disease. JAMA 2013;309(7):689–98. [PUBMED:
23423414]
Yuh 2015
Yuh B, Wilson T, Bochner B, Chan K, Palou J, Stenzl
A, et al. Systematic review and cumulative analysis of
oncologic and functional outcomes after robot-assisted
radical cystectomy. European Urology 2015;67(3):402–22.
[PUBMED: 25560797]
∗ Indicates the major publication for the study
23Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bochner 2015
Methods • Study design: parallel RCT, expertise-based, superiority trial
• Study date: March 2010 to March 2013
• Study setting: hospital-based, single-institution study -Memorial Sloan Kettering
Cancer Center (MSKCC), USA
• Randomisation ratio: 1:1
• Study hypothesised that the rate of Clavien grade 2 to 5 complications would be
20% lower in absolute terms for RARC compared with ORC. This trial with an α of
5% and 80% power would require 93 participants per arm. However, due to a
mandated interim analysis to occur halfway through enrolment, the study intended to
accrue 105 participants per arm to maintain 80% power. For the interim analysis,
study authors would calculate the upper bound of a one-sided 95% CI for the
difference in rate of Clavien grade 2 to 5 complications between surgery groups. If the
upper bound was 20%, they would stop the trial for futility.
Participants Adults undergoing radical cystectomy (n = 118)
Diagnostic criteria:
• Bladder cancer with clinical stage Ta-T3/N0-3/M0
Inclusion criteria:
• Medically cleared for RC plus PLND
• Aged 18 years
• Clinical stage Ta-T3/N0-3/M0
Exclusion criteria:
• Previous pelvic radiation
• Clinical stage T4 or M1
• Any contraindication for Trendelenburg position, or extensive prior abdominal
surgery
Demographic data: RARC vs ORC
Median age years (IQR) = 66 (60 to 71) vs 65 (58 to 69)
Male sex, n (%) = 51 (85) vs 42 (72)
Body mass index, kg/m², median (IQR) = 27.9 (24.7 to 31.0) vs 29.0 (26.3 to 33.7)
Interventions Cohort 1 = ORC with urinary diversion and PLND (n = 58)
Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 60)
• Men underwent removal of the prostate if present, and women underwent
hysterectomy and bilateral salpingo-oophorectomy if organs were present.
• Lymphadenectomy template: The extent of the PLND was left to the discretion
of the surgeon based on clinician preference and judgement (extent of disease, vascular
disease) and was determined before randomisation. The extent of PLND was alterable
intraoperatively based on clinical findings (vascular disease, fibrosis, adenopathy).
• Surgeon experience: This is an expertise-based study. All RARC procedures were
performed by 1 of 3 surgeons with extensive robotic pelvic surgery experience. All
urinary diversions were performed as open surgeries; therefore, 1 of the surgeons
experienced in open procedures completed them, regardless of the randomisation arm.
All surgeons were urological oncology fellowship trained and had a minimum of 10
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Bochner 2015 (Continued)
years’ operative experience in practice after fellowship.
• Number of conversions from RARC to ORC: 0
• Number of participant crossovers to ORC after randomising to RARC: 4
(patient refusal to have RARC)
Outcomes • Primary outcomes
◦ Overall 90-day grade 2 to 5 complications defined by a modified Clavien
system
• Secondary outcomes included
◦ Comparison of high-grade complications
◦ Estimated blood loss
◦ Operative time
◦ Pathological outcomes
◦ 3- and 6-month patient-reported QoL outcomes
◦ Total operative room and inpatient costs
• ITT analysis performed
Funding sources This study was supported by the Sidney Kimmel Center for Prostate and Urologic
Cancers atMemorial Sloan KetteringCancer Center, Pin Down Bladder Cancer, and the
Michael and Zena Wienerfor Therapeutics Program in Bladder Cancer. Study sponsors
were involved in the design and conduct of the study; in collection, analysis,management,
and interpretation of the data; and in preparation, review, and approval of themanuscript
Declarations of interest None
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote frompublication: “Consentingpa-
tients were stratified by age (64 vs 65 yr)
and American Society of Anesthesiologists
score (1-2 vs 3-4), then randomly assigned
1:1 to undergo RARC or ORC using ran-
domly permuted blocks of random length.
”
Comment: adequate random sequence
generation performed
Allocation concealment (selection bias) Low risk Quote from publication: “Randomiza-
tion was conducted by an independent of-
fice, where allocation concealment was en-
sured by a password-protected database,
such that the randomization group could
not be predicted prior to receiving group as-
signment and group could not be changed
after randomization.”
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Comment: adequate allocation conceal-
ment
Blinding of participants and personnel
(performance bias)
High risk Comment: participants and personnel not
blinded
Blinding of outcome assessment (detection
bias)
Recurrence Free Survival
Unclear risk Comment: Trial does not explicitly state
who collected these data.
Blinding of outcome assessment (detection
bias)
QOL
High risk Comment: participant-reported
outcomes; participants not blinded
Blinding of outcome assessment (detection
bias)
Complications
High risk Quote from publication: “All complica-
tionswere graded on theMSKCCmodified
Clavien grading scale. Complications data
were collected prospectively by unblinded
MSKCC research study staff at the initial
postoperative, 3-mo, and 6-mo follow-up
visits using the institution’s standard re-
porting method for postoperative compli-
cations.”
Comment: assessor unblinded
Blinding of outcome assessment (detection
bias)
Transfusion Rates
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
Hospital Stay
Low risk Comment: unlikely to be affected by non-
blinding
Blinding of outcome assessment (detection
bias)
Positive Margin Rates
Low risk Quote from publication: “All pathologic
specimens were reviewed blinded to surgi-
cal technique.”
Comment: adequate blinding; addition-
ally, regardless of blinding, low risk of de-
tection bias
Incomplete outcome data (attrition bias)
Complications/Transfusion/Hospital Stay/
Positive Margins
Low risk Comment: All randomised participants
were included in the analysis for these out-
comes
Incomplete outcome data (attrition bias)
QOL
High risk Quote from publication: “Fifty-eight pa-
tients returned evaluable baseline surveys
and 53 returned follow-up surveys at 3 and
6 mo.”
Comment: In the RARC group, 60 par-
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Bochner 2015 (Continued)
ticipants were randomised, and 30 (50%)
participants returned surveys at 6 months.
In the ORC group, 58 participants were
randomised, and 22 (38%) participants re-
turned surveys at 6 months
Incomplete outcome data (attrition bias)
Recurrence Free Survival
Low risk Comment: All randomised participants
were included in the analysis.
Selective reporting (reporting bias) Low risk All predefined outcomes were reported for
both groups in the time period suggested
Other bias Low risk Comment: not detected
Khan 2016
Methods • Study design: randomised controlled 3-arm parallel-group, expertise-based,
superiority trial
• Study date: March 2009 to July 2012
• Study setting: hospital setting -Guy’s Hospital, London, UK
• Study authors estimated the RARC complication rate as 10% to 15% and the
ORC complication rate as 25% to 60%. Therefore, the number needed in each arm
ranges from 43 to 58, so the 95% CI for the estimated difference in rates is 16%. Based
on these considerations, researchers aimed to recruit 47 participants per arm. A 3-year
interim analysis suggests no significant differences in primary outcomes between arms,
and, coupled with recruitment difficulties, the institutional research project steering
board recommended terminating the trial at that point.
Participants Adults undergoing radical cystectomy (n = 60)
Diagnostic criteria:
• MIBC and high-risk NMIBC
Inclusion criteria:
• Participants between 18 and 80 years of age requiring RC for MIBC or high-risk
NMIBC
Exclusion criteria:
• Unsuitable for laparoscopic radical cystectomy or robotic-assisted radical
cystectomy due to severe cardiorespiratory comorbidities
• Extensive abdominopelvic surgery or radiation
Demographic data: RARC vs ORC
Mean age years (SD) = 68.6 (6.8) vs 66.6 (8.8)
Male sex, n (%) = 17 (85) vs 18 (90)
Body mass index, kg/m², mean (SD) = 27.5 (4.2) vs 27.4 (3.9)
Interventions Cohort 1 = ORC with urinary diversion and PLND (n = 20)
Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 20)
Cohort 3 = LRC with extracorporeal urinary diversion and PLND (n = 20)
• All neobladders were fashioned using the Studer technique.
• Lymphadenectomy template: obturator, external/internal/common iliac, and
presacral nodes
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• Surgeon experience: This is an expertise-based study. At trial initiation, the ORC
surgeon had performed > 150 ORCs and the RARC surgeon had performed 110
RARCs.
• Number of conversions from RARC to ORC: 0
• Number of participant cross-overs to ORC after randomising to RARC: 1
(equipment failure)
Outcomes • Primary end points
◦ 30- and 90-day complication rates
• Secondary end points
◦ Perioperative parameters (operative time, EBL, delay in bowel function, and
LOS)
◦ Pathological outcomes (margin status and number of lymph nodes retrieved)
◦ 12-month oncological outcomes
◦ QoL -study authors do not state in the methodology when they plan to assess
Funding sources The research, including statistical support (Jennifer A. Summers and Janet L. Peacock)
, was supported by the National Institute for Health Research (NIHR) Biomedical
Research Centre, based at Guy’s and St. Thomas’ NHS Foundation Trust and King’s
College London. Prokar Dasgupta and Kamran Ahmed acknowledge support from the
NIHR Biomedical Research Centre, Medical Research Council Centre for Transplanta-
tion, King’s Health Partners, Guy’s and St. Thomas’ Charity, School of Surgery, London
Deanery, Royal College of Surgeons of England, Intuitive Surgical, The Urology Foun-
dation, Olympus, EU-FP7, ProstateCancer UK, Technology Strategy Board, and The
Vattikuti Foundation
Declarations of interest None
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Randomisa-
tionwas undertaken by the trial nurse (J.W.
) using identical sealed opaque envelopes,
each containing a piece of paper designat-
ing the surgical modality (ORC, LRC, or
RARC). Simple randomisation was per-
formed in two groups of 30. In each group,
each modality was allocated 10 envelopes.
These were shuffled and then numbered 1-
30. Patients received the next envelope in
numerical order.”
Comment: random sequence generation
adequate
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Allocation concealment (selection bias) Low risk Quote frompublication: “Envelopes were
kept in a locked room, accessed only by the
trial nurse to minimise opportunities for
tampering, and they were opened by the
patient in the presence of three members of
the research team to ensure that no changes
were made to allocation.”
Comment: allocation concealment ade-
quate
Blinding of participants and personnel
(performance bias)
High risk Comment: participants and personnel not
blinded
Blinding of outcome assessment (detection
bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
QOL
High risk Quote from publication: “This study was
nonblinded because the different incisions
would be difficult to camouflage.”
Comment: participant-reported
outcomes; participants not blinded
Blinding of outcome assessment (detection
bias)
Complications
High risk Quote from publication: “This study was
nonblinded because the different incisions
would be difficult to camouflage.”
Comment: no outcome assessor blinding;
study does not report the assessor
Blinding of outcome assessment (detection
bias)
Transfusion Rates
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
Hospital Stay
Low risk Comment: unlikely to be affected by non-
blinding
Blinding of outcome assessment (detection
bias)
Positive Margin Rates
Low risk Comment: unlikely to be affected by non-
blinding
Incomplete outcome data (attrition bias)
Complications/Transfusion/Hospital Stay/
Positive Margins
Low risk Comment: All randomised participants
were included in the analysis for these out-
comes
Incomplete outcome data (attrition bias)
QOL
High risk Quote from publication: “Overall, 53 pa-
tients completed the QoL questionnaire.
One questionnaire was analysed per patient
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(average 8mopostoperatively). Incomplete
questionnaires were excluded.”
Comment: In the RARC group, 20 par-
ticipants were randomised, and 15 (75%)
participants returned surveys. In the ORC
group, 20 participants were randomised,
and 16 (80%) participants returned surveys
Incomplete outcome data (attrition bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Selective reporting (reporting bias) Low risk Comment: predefined outcomes reported
for both groups in the time period sug-
gested
Other bias Low risk Comment: not detected
Nix 2010
Methods • Study design: randomised noninferiority single-centre study
• Study period: April 2008 and January 2009
• Study setting: hospital based -University of North Carolina at Chapel Hill,
Chapel Hill, North Carolina, USA
• LN yield was selected as the primary end point used for power analysis
• The null hypothesis was that mean LN yield for open cystectomy was higher than
that for robotic cystectomy. A sample size of 20 participants per arm was calculated to
provide 80% power and a 0.05 type 1 error rate to demonstrate the noninferiority of
open to robotic cystectomy with respect to LN count based on a critical difference of 4
LNs. The 90% one-sided CI of this difference is reported because of the 5%
significance used for the sample size calculation. If the upper level of this CI is > 4, the
null hypothesis cannot be rejected and noninferiority has not been achieved.
Participants Adults undergoing radical cystectomy (n = 41)
Diagnostic and inclusion criteria:
• Clinically localised urothelial carcinoma of the bladder
• Decision for surgical candidacy was based on the participant’s overall health status
primarily with regard to ability to tolerate the pneumoperitoneum and steepness of the
Trendelenburg position associated with the robotic approach.
Exclusion criteria:
• Unsuitable surgical candidates for either approach
• Those not allowing randomisation
• Those with preconceived preference for a specific surgical modality
Interventions Cohort 1 = ORC with urinary diversion and PLND (n = 20)
Cohort 2 = RARC with extracorporeal urinary diversion and PLND (n = 21)
• Lymphadenectomy template: obturator, external iliac, hypogastric, and
common iliac LN chains (did not include a paraaortic or paracaval dissection)
• Surgeon experience:
◦ Experience of > 75 robotic cystectomy cases and of > 400 open cystectomy
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procedures
◦ Same primary surgeon and experienced surgical team in both groups
Demographic data: RARC vs ORC
Mean age years = 67.4 vs 69.2
Male:Female = 14:7 vs 17:3
Body mass index, kg/m², mean = 27.5 vs 28.4
Outcomes • EBL
• Operative time
• Complications
• Recovery of bowel function
• Narcotic usage
• Length of stay when assessed
• Margin status
• Lymph node count
• Time to adjuvant chemotherapy
Funding sources None
Declarations of interest None
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “The random-
izations schemawas performedwith five se-
quential patients undergoing an approach
before alternating surgical modality.”
Comment: random sequence generation
adequate
Allocation concealment (selection bias) High risk Quote from publication: “The random-
ization schema was performed with five se-
quential patients undergoing an approach
before alternating surgical modality. This
scheme was chosen, as opposed to random-
izing each sequential patient, for the pur-
pose of resident education. We believed
that alternating each sequential surgery as
to approach would make it significantly
more difficult for residents to progress
through their knowledge and acquisition of
proficiency in each of the individual proce-
dures.”
Comment: allocation concealment inade-
quate
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Blinding of participants and personnel
(performance bias)
High risk Comment: participants and personnel not
blinded
Blinding of outcome assessment (detection
bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
QOL
Unclear risk Comment: not applicable as not reported
Blinding of outcome assessment (detection
bias)
Complications
Unclear risk Comment:no report onwho collected out-
comes and if they were blinded to the pro-
cedure
Blinding of outcome assessment (detection
bias)
Transfusion Rates
Unclear risk Comment: not applicable as not reported
Blinding of outcome assessment (detection
bias)
Hospital Stay
Low risk Comment: unlikely to be affected by non-
blinding
Blinding of outcome assessment (detection
bias)
Positive Margin Rates
Low risk Comment: unlikely to be affected by non-
blinding
Incomplete outcome data (attrition bias)
Complications/Transfusion/Hospital Stay/
Positive Margins
Low risk Comment: all randomised participants in-
cluded in analysis for these outcomes
Incomplete outcome data (attrition bias)
QOL
Unclear risk Comment: not applicable as not reported
Incomplete outcome data (attrition bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Selective reporting (reporting bias) Unclear risk No protocol published
Other bias Low risk None
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Methods • Study design: pilot prospective RCT
• Study date: July 2009 to June 2011
• Study setting: single-institution study-University of Texas Health Sciences Center
at San Antonio, San Antonio, Texas, USA
• Pilot trial to establish
◦ Feasibility and safety of the robotic approach
◦ Preliminary data to determine statistical analyses and outcome measures for
a phase 3 multi-institutional clinical trial
Participants Adults undergoing radical cystectomy (n = 40)
Diagnostic criteria:
• Biopsy-proven bladder cancer of clinical stage T1-T3, N0, M0
Inclusion criteria:
• Candidates for an open or robotic approach at the discretion of the treating
surgeon
Exclusion criteria:
• Inability to give informed consent
• Multiple prior abdominal and pelvic open surgical procedures that would
preclude a safe robotic approach
• Morbid obesity that would preclude the robotic approach
• Clinical T4 bladder cancer
• Clinical lymph node-positive bladder cancer with grossly enlarged pelvic or
retroperitoneal lymph nodes
• Any preexisting condition that precludes safe initiation or maintenance of
pneumoperitoneum for a prolonged period
• Age younger than 30 or older than 90 years
• Pregnancy
Demographic data: RARC vs ORC
Median age years (IQR) = 69.5 (62.3 to 74) vs 64.5 (59.8 to 72.3)
Male:Female = 18:2 vs 16:4
Body mass index, kg/m², median (IQR) = 27.6 (24.2 to 29.9) vs 28.3 (26.1 to 32.3)
Interventions Cohort 1 = ORC with urinary diversion and PLND (n = 20)
Cohort 2 = RARC with open urinary diversion and PLND (n = 20)
• The type of urinary diversion was performed at the discretion of the surgeon. The
study does not explicitly state if the urinary diversion was performed with an
extracorporeal or intracorporeal approach.
• Lymphadenectomy template: Lymph node dissection for both groups was
performed superiorly to the level of the ureteral crossing of the common iliac vessels,
including the internal iliac artery and the obturator fossa, and laterally to the
genitofemoral nerve, including the tissue overlying the psoas muscle.
• Surgeon experience: The primary faculty involved in the study had an
independent experience of more than 100 ORCs and had performed approximately 50
RARCs.
• Number of conversions from RARC to ORC: 0
• Number of participant cross-overs to ORC after randomising to RARC: 0
Outcomes • Establish the feasibility of randomising participants
• Obtain preliminary data on oncological efficacy, perioperative outcomes, and
HRQoL outcomes
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• Evaluate HRQoL using the FACT-VCI questionnaire preoperatively, and then at
3, 6, 9, and 12 months postoperatively
Funding sources Not reported in the study
Declarations of interest None
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from publication: “Patients who
met the inclusion criteria were randomized
to open or robotic radical cystectomy at
their preoperative clinic visit using a com-
puterized randomization program (www.
randomization.com) (see figure). This pro-
gram generated a list of surgical slots num-
bered 1 through 60, and randomly assigned
open or robotic assisted cystectomy to each
slot (30 slots for each procedure).”
Comment: random sequence generation
adequate
Allocation concealment (selection bias) Low risk Quote from publication: “Each assign-
ment was placed in a sealed envelope with
the corresponding slot number written on
the outside. At the time of consent the
lowest numbered envelope remaining was
opened and the patient was assigned to the
surgical procedure listed on the piece of pa-
per inside the envelope.”
Comment: allocation concealment ade-
quate
Blinding of participants and personnel
(performance bias)
High risk Comment: participants and personnel not
blinded
Blinding of outcome assessment (detection
bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Blinding of outcome assessment (detection
bias)
QOL
High risk Quote from publication: “The surgical
team and the patient were thenmade aware
of the type of surgery.”
Comment: Participants were aware of the
approach they had; hence there would have
34Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Parekh 2013 (Continued)
been an expectation bias when they com-
pleted their QoL questionnaires. Partici-
pant-reported outcomes. Participants not
blinded
Blinding of outcome assessment (detection
bias)
Complications
Unclear risk Comment: The study does not state who
the outcome assessor was; it is unclear if the
assessor was blinded
Blinding of outcome assessment (detection
bias)
Transfusion Rates
Low risk Comment: unlikely to be affected by non-
blinding
Blinding of outcome assessment (detection
bias)
Hospital Stay
Low risk Comment: unlikely to be affected by non-
blinding
Blinding of outcome assessment (detection
bias)
Positive Margin Rates
Low risk Comment: unlikely to be affected by non-
blinding
Incomplete outcome data (attrition bias)
Complications/Transfusion/Hospital Stay/
Positive Margins
Low risk Comment: Most randomised participants
were included in the analysis for these out-
comes
Incomplete outcome data (attrition bias)
QOL
High risk Quote from second publication: “The
study is limited by the response rate to the
questionnaires, with sampling at only 50%
for some time periods, which only under-
scores the difficulty of obtaining prospec-
tive data with regard to HRQoL.”
Comment: Reported in the second pub-
lication. In the RARC group, 20 partici-
pants were randomised, and 12 (60%) par-
ticipants returned surveys at 12 months.
In the ORC group, 20 participants were
randomised, and 13 (65%) participants re-
turned surveys at 12 months
Incomplete outcome data (attrition bias)
Recurrence Free Survival
Unclear risk Comment: not reported
Selective reporting (reporting bias) Low risk All predefined outcomes measured
Other bias Low risk None
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Methods • Study design: multicentre, open-label, randomised, phase 3, noninferiority trial
• Study setting: 15 medical centres in the USA
Participants Adults undergoing radical cystectomy
Diagnostic criteria and inclusion criteria:
• Biopsy-proven clinical stage T1-T4, N0-N1, M0 bladder cancer or refractory
carcinoma in situ
• Age of 18 years or older
Exclusion criteria:
• Open abdominal or pelvic surgery or any preexisting health condition that would
preclude safe initiation or maintenance of pneumoperitoneum
• Pregnant women
Interventions Intention-to-treat analysis
Cohort 1 = ORC with urinary diversion and PLND (n = 159)
Cohort 2 = RARC with open urinary diversion and PLND (n = 153)
• All urinary diversions were extracorporeal.
• Lymphadenectomy template: Extent of pelvic lymph node dissection (standard
or extended) was based on institutional preference.
• Surgeon experience: Surgeons performing RARC and/or ORC must have
performed ≥ 10 procedures each over the 1 year before approval as a study site.
• Use of chemotherapy was based on institutional preference.
Outcomes Primary outcome
• 2-year progression-free survival
Quote from publication: “Disease progression was determined on the basis of radio-
graphical or pathological evidence of disease, or death from disease according to Re-
sponse Evaluation Criteria in Solid Tumours criteria version 1.1.”
Secondary outcomes
• Blood loss
• Blood transfusion rates
• Surgical margin status
• Number of lymph nodes
• Operating time
• Length of hospital stay
• 90-day surgical complications
• 3- and 6-month health-related QoL outcomes
• Quote from publication: “Change in baseline serum haemoglobin, creatinine,
and albumin concentrations at 4-6 weeks, and at 3, 6, 12, 24, and 36 months,
intraoperative fluid requirements, and analgesic requirements.”
Exploratory end points
• Overall survival
• Quote from publication: “Activities and instrumental activities of daily living
scores, hand grip strength, and timed up and go walking test outcomes, assessed at 4-6
weeks, 3 months, and 6 months.”
Funding sources National Institutes of Health National Cancer Institute
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Declarations of interest Quote from publication: “EPC reports personal fees from Intuitive Surgical outside
the submitted work. MEW reports grants from the National Institutes of Health (NIH)
during the study, and outside the submitted work. AZW reports grants from the Uni-
versity of Michigan during the study. BRK reports grants from the National Cancer
Institute during the study; and grants from Photocure, Roche-Genentech, Genomic
Health, Myriad Genetics, Spectrum, and FKD Therapies, outside the submitted work.
MT reports grants from the NIH during the study. TLK reports grants from the NIH
during the study. DAB reports grants from the NIH, during the study; and personal fees
from AstraZeneca, Tolmar Pharmaceuticals, and Janssen, outside the submitted work.
ASK reports advisory board fees from Profound, Sanofi-Aventis, and Janssen, outside
the submitted work. CJW reports grants from Myriad Genetics and personal fees from
Abbott Molecular, outside the submitted work. MSC has served on advisory boards for
Astellas Pharma US, MDxHealth, Janssen, Bayer Healthcare, CicloMed, Abbott Lab-
oratories, Tolmar Pharmaceuticals, Genomic Health, Altor Bioscience, Photocure, and
Takeda Pharmaceutical; and reports consultancy fees from Myovant Sciences, TesoRx
Pharma, and Pacific Edge Diagnostics. All other authors declare no competing interests.
”
Notes Language of publication: English
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote from study: “By use of a dynamic
balancing algorithm, patients were cen-
trally randomly assigned (1:1) via a web-
based system, to receive open cystectomy
or robotic cystectomy. Using each insti-
tution as a block, the dynamic allocation
procedure allocated an approximately equal
number of patients to treatment groups
to minimise imbalance between groups,
stratified by type of urinary diversion (in-
continent or continent), clinical T stage
(carcinoma in situ, T1-T2, or T3-T4),
and Eastern Cooperative Oncology Group
(ECOG) performance status (0-1, or =2).
On accrual a hierarchical decision-rule was
applied, and the allocation was determin-
istic if certain predefined limits were ex-
ceeded, and random otherwise.”
Allocation concealment (selection bias) Low risk Quote from study: “By use of a dynamic
balancing algorithm, patients were cen-
trally randomly assigned (1:1) via a web-
based system, to receive open cystectomy
or robotic cystectomy. Using each insti-
tution as a block, the dynamic allocation
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procedure allocated an approximately equal
number of patients to treatment groups
to minimise imbalance between groups,
stratified by type of urinary diversion (in-
continent or continent), clinical T stage
(carcinoma in situ, T1-T2, or T3-T4),
and Eastern Cooperative Oncology Group
(ECOG) performance status (0-1, or =2).
On accrual a hierarchical decision-rule was
applied, and the allocation was determin-
istic if certain predefined limits were ex-
ceeded, and random otherwise.”
Blinding of participants and personnel
(performance bias)
High risk Comment: in view of the nature of the
study, unlikely to be blinded
Quote from study: “Treatment allocation
was only masked from pathologists, who
analysed the cystectomy specimens.”
Blinding of outcome assessment (detection
bias)
Recurrence Free Survival
High risk Quote from study: “Treatment allocation
was only masked from pathologists, who
analysed the cystectomy specimens.”
Blinding of outcome assessment (detection
bias)
QOL
High risk Quote from study: “Treatment allocation
was only masked from pathologists, who
analysed the cystectomy specimens.”
Blinding of outcome assessment (detection
bias)
Complications
High risk Quote from study: “Treatment allocation
was only masked from pathologists, who
analysed the cystectomy specimens.”
Blinding of outcome assessment (detection
bias)
Transfusion Rates
Low risk Unlikely to be affected by nonblinding
Blinding of outcome assessment (detection
bias)
Hospital Stay
Low risk Unlikely to be affected by nonblinding
Blinding of outcome assessment (detection
bias)
Positive Margin Rates
Low risk Quote from study: “Treatment allocation
was only masked from pathologists, who
analysed the cystectomy specimens.”
Comment:Unlikely to be affected by non-
blinding
Incomplete outcome data (attrition bias)
Complications/Transfusion/Hospital Stay/
Positive Margins
Low risk Comment: Most randomised participants
were included in analysis for these out-
comes
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Incomplete outcome data (attrition bias)
QOL
High risk Comment: At 6 months, QoL data were
available for only 198 participants (63.4%)
Incomplete outcome data (attrition bias)
Recurrence Free Survival
Unclear risk Quote from study: “Between July 1, 2011,
and Nov 18, 2014, 350 patients were ran-
domly assigned to treatment: 176 to the
robotic cystectomy group and 174 to the
open cystectomy group. Of the 176 pa-
tients who were randomly assigned to re-
ceive robotic cystectomy, 17 (10%)patients
did not have surgery and nine (5%) pa-
tients had a different surgery to that they
were assigned. Of the 174 patients assigned
to receive open cystectomy, 21 (12%) pa-
tients did not have surgery and one (1%)
patient had robotic cystectomy instead of
open cystectomy.”
Selective reporting (reporting bias) Low risk Comment: all predefined outcomes mea-
sured
Other bias Low risk Comment: nil
CI: confidence interval; EBL: estimated blood loss; FACT-VCI: Functional Assessment of Cancer Therapy -Vanderbilt Cystectomy
Index; HRQoL: health-related quality of life; IQR: interquartile range; ITT: intention-to-treat; LN: lymph node; LOS: length of
(hospital) stay; LRC: laparoscopic radical cystectomy;MIBC: muscle-invasive bladder cancer; NMIBC: non-muscle-invasive bladder
cancer; ORC: open radical cystectomy; PLND: pelvic lymph node dissection; QoL: quality of life; RARC: robotic-assisted radical
cystectomy; RC: radical cystectomy; RCT: randomised controlled clinical trial; SD: standard deviation.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2013 Not a randomised controlled study. In this study, benign ureteroenteric anastomotic stricture rates of open and
robot assisted laparoscopic radical cystectomy were compared using a prospectively maintained database
Atmaca 2015 Not a randomised controlled study. Retrospective comparison of open vs totally intracorporeal robotic-assisted
radical cystectomy, bilateral extended pelvic lymph node dissection, and Studer urinary diversion. Researchers
evaluated operative and postoperative parameters, pathological parameters, complications, and functional
outcomes
Bak 2016 Although not clearly specified, this appears to be a nonrandomised retrospective observational study
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Borza 2017 Not a randomised controlled study. Participants were identified from International Classification of Diseases
9th edition codes and administrative claims from a large, national US health insurer. This study compared
readmission rates for ORC and RARC
Cusano 2016 Not a randomised controlled study. Retrospective comparison of preliminary oncological outcomes for ORC
and RARC
Galich 2006 Not a randomised controlled study. This study compared early perioperative outcomes following radical cys-
tectomy by the robotic method vs the conventional open method using a prospectively maintained database
Gandaglia 2016 Not a randomised controlled study. Retrospective comparison of perioperative and oncological outcomes of
open (ORC) and robotic-assisted radical cystectomy (RARC) between 2 large-volume European centres
Ginot 2016 Not a randomised controlled study. Comparison of robotic-assisted cystectomy vs open cystectomy, with
urinary diversion by bladder substitution
Gondo 2012 Not a randomised controlled study. This study compared early perioperative outcomes following radical cys-
tectomy by the robotic method vs the conventional open method using a prospectively maintained database
in a Japanese population
Khan 2012 Not a randomised controlled study. This prospective study compared perioperative outcomes of ORC, RARC,
and LRC
Koupparis 2015 Not a randomised controlled study. This study compared the impact of ERAS between prospective RARC data
and retrospectively maintained ORC data
Lee 2011 Not a randomised controlled study. This prospective comparative study compared the economic burden of
ORC vs RARC
Li 2016 Not a randomised controlled study. This retrospective study compared health-related quality of life (HRQoL)
and short-term convalescence among bladder cancer patients who underwent ORC and RARC
Martin 2011 Not a randomised controlled study. This prospective comparative study performed cost analysis of ORC and
RARC
Matulewicz 2016 Not a randomised controlled study. Researchers used the National Cancer Data Base to compare oncological
quality indicators between open and robotic-assisted radical cystectomy
Musch 2014 Not a randomised controlled study.This prospective comparative study compared early postoperativemorbidity
of ORC and RARC
Nepple 2013 Not a randomised controlled study. This retrospective non-matched study compared pathology, recurrence,
and survival between ORC and RARC
Ng 2010 Not a randomised controlled study. This prospective study compared complications between ORC and RARC
Nguyen 2015 Not a randomised controlled study. This retrospective study compared RFS and recurrence patterns between
ORC and RARC
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Rhee 2006 Not a randomised controlled study. This prospective comparative study compared estimated blood loss (EBL)
, transfusion requirements, operative duration, hospital stay, and body mass index (BMI) between ORC and
RARC
Satkunasivam 2016 Not a randomised controlled study. This retrospective study compared urodynamic features of intracorporeal
orthotopic neobladder and bladder cancer-specific and general health-related quality of life between RARC
and ORC
Sharma 2017 Not a randomised controlled study.This retrospective study compared pathological andpostoperative outcomes
of RARC vs open radical cystectomy (ORC) with high-risk disease (pT3/T4)
Styn 2012 Not a randomised controlled study. Thismatched-pair analysis comparedORC andRARC.Researchersmatch-
paired age, sex, urinary diversion, and clinical stage, and they compared perioperative complications and
pathological outcomes
Tan 2016 Not a randomised controlled study. Investigators compared early oncological outcomes and cancer recurrence
sites among patients undergoing ORC and RARC with intracorporeal urinary diversion (iRARC)
Wang 2008 Not a randomised controlled study. This prospective study compared estimated blood loss (EBL), transfusion
requirement, operative duration, time to resumption of regular diet, hospital stay, complication rates, and
pathological outcomes between ORC and RARC
Winters 2016 Not a randomised controlled study. This study compared perioperative surgical outcomes among elderly
patients
BMI: body mass index; EBL: estimated blood loss; ERAS: Enhanced recovery after syrgery; HRQoL: health-related quality of life;
iRARC: intracorporeal urinary diversion; LRC: laparoscopic radical cystectomy; ORC: open radical cystectomy; RARC: robotic-
assisted radical cystectomy; RFS: Recurrence-free survival.
Characteristics of ongoing studies [ordered by study ID]
Kelly , Catto 2017
Trial name or title IROC (Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy)
Methods Phase III multicentre randomised controlled trial
Participants Patients with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) who
had selected radical cystectomy for treatment of bladder cancer; planned accrual of 320 participants
Interventions Robotically assisted radical cystectomy and intracorporeal urinary diversion vs open radical cystectomy
Outcomes Primary outcome measures:
• Days at home within 90 days of surgery
Secondary outcome measures:
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• by WHODAS version 2.0
• Quality of life measured by EQ-5D-5L Health Questionnaire and EORTC QLQ-C30 version 3
Starting date 01/03/2017 (estimated study completion date: 15 February 2020)
Contact information Chris Brew-Graves; 0207 679 9280; situ.iroc@ucl.ac.uk
Notes ClinicalTrials.gov identifier (NCT number): NCT03049410
EORTCQLQ-C30: EuropeanOrganisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; EQ-5D-5L:
EuroQol 5 Domains 5 Levels; MIBC: muscle-invasive bladder cancer; NMIBC: non-muscle-invasive bladder cancer; WHODAS:
World Health Organization Disability Assessment Schedule.
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Comparison 1. Robotic-assisted laparoscopic versus open radical cystectomy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Recurrence-free survival 2 430 Hazard Ratio (Random, 95% CI) 1.05 [0.77, 1.43]
2 Major postoperative
complication rates (Clavien 3
to 5)
5 541 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.76, 1.48]
3 Minor postoperative
complication rates (Clavien 1
and 2)
4 423 Risk Ratio (M-H, Random, 95% CI) 0.82 [0.58, 1.17]
4 Transfusion rate 2 326 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.43, 0.80]
5 Hospital stay 5 541 Mean Difference (IV, Random, 95% CI) -0.67 [-1.22, -0.12]
6 Quality of life 3 270 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.32, 0.16]
7 Positive margin 5 541 Risk Ratio (M-H, Random, 95% CI) 1.16 [0.56, 2.40]
Analysis 1.1. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 1
Recurrence-free survival.
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 1 Recurrence-free survival
Study or subgroup RARC ORC log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Bochner 2015 60 58 0.239 (0.284) 31.5 % 1.27 [ 0.73, 2.22 ]
Parekh 2018 159 153 -0.0408 (0.1924) 68.5 % 0.96 [ 0.66, 1.40 ]
Total (95% CI) 219 211 100.0 % 1.05 [ 0.77, 1.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
Test for subgroup differences: Not applicable
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Analysis 1.2. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 2
Major postoperative complication rates (Clavien 3 to 5).
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 2 Major postoperative complication rates (Clavien 3 to 5)
Study or subgroup RARC ORC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bochner 2015 13/60 12/58 23.3 % 1.05 [ 0.52, 2.10 ]
Khan 2016 7/20 4/20 10.1 % 1.75 [ 0.61, 5.05 ]
Nix 2010 1/21 1/20 1.6 % 0.95 [ 0.06, 14.22 ]
Parekh 2013 1/20 1/20 1.6 % 1.00 [ 0.07, 14.90 ]
Parekh 2018 33/150 34/152 63.5 % 0.98 [ 0.64, 1.50 ]
Total (95% CI) 271 270 100.0 % 1.06 [ 0.76, 1.48 ]
Total events: 55 (RARC), 52 (ORC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.99, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.75)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.3. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 3
Minor postoperative complication rates (Clavien 1 and 2).
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 3 Minor postoperative complication rates (Clavien 1 and 2)
Study or subgroup RARC ORC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Khan 2016 4/20 10/20 11.6 % 0.40 [ 0.15, 1.07 ]
Nix 2010 6/21 9/20 15.3 % 0.63 [ 0.28, 1.46 ]
Parekh 2013 4/20 4/20 7.6 % 1.00 [ 0.29, 3.45 ]
Parekh 2018 68/150 71/152 65.6 % 0.97 [ 0.76, 1.24 ]
Total (95% CI) 211 212 100.0 % 0.82 [ 0.58, 1.17 ]
Total events: 82 (RARC), 94 (ORC)
Heterogeneity: Tau2 = 0.03; Chi2 = 3.74, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 1.08 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 1.4. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 4
Transfusion rate.
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 4 Transfusion rate
Study or subgroup RARC ORC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Parekh 2013 8/20 10/20 19.9 % 0.80 [ 0.40, 1.60 ]
Parekh 2018 35/143 65/143 80.1 % 0.54 [ 0.38, 0.76 ]
Total (95% CI) 163 163 100.0 % 0.58 [ 0.43, 0.80 ]
Total events: 43 (RARC), 75 (ORC)
Heterogeneity: Tau2 = 0.00; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 5
Hospital stay.
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 5 Hospital stay
Study or subgroup RARC ORC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bochner 2015 60 8 (3) 58 8 (5) 10.7 % 0.0 [ -1.49, 1.49 ]
Khan 2016 20 11.9 (6.2) 20 14.4 (5.9) 2.1 % -2.50 [ -6.25, 1.25 ]
Nix 2010 21 5.1 (2.41) 20 6 (2.41) 10.9 % -0.90 [ -2.38, 0.58 ]
Parekh 2013 20 6.625 (1.125) 20 6.83 (0.825) 30.3 % -0.20 [ -0.81, 0.41 ]
Parekh 2018 150 6 (0.833) 152 7 (0.66) 46.1 % -1.00 [ -1.17, -0.83 ]
Total (95% CI) 271 270 100.0 % -0.67 [ -1.22, -0.12 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 8.29, df = 4 (P = 0.08); I2 =52%
Test for overall effect: Z = 2.38 (P = 0.017)
Test for subgroup differences: Not applicable
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Analysis 1.6. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 6
Quality of life.
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 6 Quality of life
Study or subgroup RARC ORC
Std.
Mean
Difference Weight
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Bochner 2015 23 76 (11) 30 78 (23) 19.4 % -0.10 [ -0.65, 0.44 ]
Khan 2016 15 122.3 (17.1) 16 124.9 (12.7) 11.5 % -0.17 [ -0.87, 0.54 ]
Parekh 2018 95 126 (27.8) 91 127.5 (28.2) 69.2 % -0.05 [ -0.34, 0.23 ]
Total (95% CI) 133 137 100.0 % -0.08 [ -0.32, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Test for subgroup differences: Not applicable
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Analysis 1.7. Comparison 1 Robotic-assisted laparoscopic versus open radical cystectomy, Outcome 7
Positive margin.
Review: Robotic versus open radical cystectomy for bladder cancer in adults
Comparison: 1 Robotic-assisted laparoscopic versus open radical cystectomy
Outcome: 7 Positive margin
Study or subgroup RARC ORC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bochner 2015 2/60 3/58 17.1 % 0.64 [ 0.11, 3.72 ]
Khan 2016 3/20 2/20 18.7 % 1.50 [ 0.28, 8.04 ]
Nix 2010 0/21 0/20 Not estimable
Parekh 2013 1/20 1/20 7.2 % 1.00 [ 0.07, 14.90 ]
Parekh 2018 9/150 7/152 56.9 % 1.30 [ 0.50, 3.41 ]
Total (95% CI) 271 270 100.0 % 1.16 [ 0.56, 2.40 ]
Total events: 15 (RARC), 13 (ORC)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.59, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
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Appendix 1. Electronic search strategies
Database Search terms
CENTRAL #1 MeSH descriptor: [Robotics] explode all trees
#2 (robot*):kw,ti,ab near/3 (surgery* or assist):kw,ti,ab
#3 #1 or #2
#4 MeSH descriptor: [Cystectomy] explode all trees
#5 (surg* or excis*):kw,ti,ab near/3 (urin* or bladder*):kw,ti,ab
#6 #4 or #5
#7 #3 and #6
#8 (robot*):kw,ti,ab near/3 (cystectom*):kw,ti,ab
#9 #7 or #8
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(Continued)
MEDLINE (PubMed) 1 Robotics
2 Robot
3 “Robotics”[MeSH]
4 1 OR 2 OR 3
5 Cystectomy
6 “Cystectomy” [MeSH]
7 5 OR 6
8 Randomized control trial[tw]
9 Controlled clinical trial[tw]
10 Randomized[tw]
11 Randomly[tw]
12 Trial[tw]
13 “Randomized Controlled Trial”[publication Type]
14 8 OR 9 OR 10 OR 11 OR 12 OR 13
15 4 AND 7 AND 14
Embase (Ovid) 1. (cystectomy and controlled clinical trial and robotic).af
2. (randomised controlled trial and robotic and cystectomy).af
3. (cystectomy and robotic).af.
Web of Science 1. (TOPIC:(cystostomy) AND TOPIC: (robotic))
2. ((TOPIC:(cystostomy) AND TOPIC: (robotic))AND TOPIC: (randomizedcontrolled trial))
3. TITLE: (cystectomy) AND TITLE: (robotic) AND TITLE: (randomized controlled trial)
4. TITLE: (cystectomy) AND TITLE: (randomized controlled trial)
Cancer Research UK 1. Bladder cancer trials
2. Robotic cystectomy
Institute of Cancer Research 1. Bladder cancer trials
2. Robotic cystectomy
ClinicalTrials.gov 1. robotic | bladder cancer | cystectomy | Child, Adult, Senior
2. robotic | Open Studies | bladder cancer | cystectomy
BioMed Central ISRCTN 1. robotic Remove filter within Condition: bladder cancer Remove filter Interventions: cystectomy
Remove filter
WHO ICTRP 1. bladder cancer AND cystectomy AND Robot
2. bladder cancer AND cystectomy AND Robot AND trial
Terms used robotic cystectomy
robot cystectomy
robot assisted cystectomy
robotic radical cystectomy
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C O N T R I B U T I O N S O F A U T H O R S
BR: wrote the review and contributed to data extraction and analysis, concept, and data interpretation.
JB: contributed to data extraction and analysis and drafting work.
NV: contributed to text of review and to data analysis, concept, and data interpretation.
JA: contributed to text of review and to data analysis, concept, and data interpretation.
TL: contributed to text of review and to data analysis, concept, and data interpretation.
KA: contributed to text of review and to concept.
MSK: contributed to text of review, concept, and data interpretation.
PD: contributed to text of review, concept, and data interpretation.
KG: contributed to text of review and to concept and data interpretation.
PLC: contributed to text of review and to interpretation of data and concept.
OMA: wrote the review and contributed to data extraction and analysis, concept, and data interpretation.
D E C L A R A T I O N S O F I N T E R E S T
BR: none known.
JB: none known.
NV: none known.
JA: none known.
TL: none known.
KA: none known.
MSK: none known.
PD: none known.
KG: none known.
PLC: none known.
OMA: none known.
S O U R C E S O F S U P P O R T
51Robotic versus open radical cystectomy for bladder cancer in adults (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Internal sources
• None, Other.
External sources
• None, Other.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
• None
N O T E S
We have based parts of theMethods section of the protocol for this review on a standard template developed by the Cochrane Metabolic
and Endocrine Disorders Group that has been modified and adapted for use by the Cochrane Urology Group.
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